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A recent empirical study (Jacobson et al., 1996) suggested that the Behavioral
Activation (BA) component of Beck’s Cognitive-Behavioral Therapy (CT) for
depression (Beck, Rush, Shaw, & Emery, 1979) may be as effective a treatment for
clinical depression as the full CT treatment. BA involves intervention choices that are
fewer in number and more straightforward than those contained in CT, making BA a
more efficient treatment than CT. The purpose of this study was to extend the
research on BA by administering it as a group therapy and to evaluate this treatment
in a natural setting. This was achieved by classifying 42 Community Mental Health
(CMH) outpatients with Major Depressive Disorder as either Behavioral Activation
Group Therapy (BAGT) subjects or wait-list subjects, dependent upon the latency
from screening to treatment initiation. Eight BAGT-trained therapists administered
the treatment weekly for 10 weeks at four Southwestern Michigan CMH agencies. A
co-therapy model was utilized and group sizes ranged from 6 to 11 persons.
Treatment subjects were assessed at pretreatment, posttreatment, and 3-month
follow-up using the Beck Depression Inventory-Second Edition (BDI-II) (Beck,
Steer, Ball, & Ranieri, 1996), the Revised Hamilton Rating Scale for Depression
(RHRSD) (Warren, 1996), and the Structured Clinical Interview for DSM-FV (SCID)
(First, Spitzer, Gibbon, & Williams, 1997). Wait-list subjects were assessed at
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prewaiting period, postwaiting period (which also represented pretreatment for these
subjects), posttreatment, and 3-month follow-up with the same outcome measures.
Results failed to uncover a statistically significant difference between wait-list
subjects and treatment subjects from pretreatment to posttreatment in this difficult to
treat population. However, a statistically significant difference between wait-list
subjects and treatment subjects from pretreatment to follow-up was observed.
Additionally, subjects who completed BAGT, regardless of initial classification,
experienced statistically significant reductions in depression scale scores after 10
weeks o f treatment and this trend continued at 3-month follow-up. In light o f the
increased severity of the present sample compared to the Jacobson et al. (1996)
sample, it is suggested that these findings support further investigation into BAGT as
a treatment for clinical depression.
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CHAPTER I
INTRODUCTION
In 1975, Peter Lewinsohn wrote, “Depression has been relatively neglected by
behavior therapists” (p. 19). It seems that almost 25 years later, this statement still
rings true. There are several possibilities why depression has not been a primary focus
o f behavior therapists; they all center around the notion that depressive behaviors are
difficult to operationalize. First, it is easier to observe, describe, and manage
behavioral excesses than behavioral deficits. And given that an extreme reduction or
absence of particular behaviors marks depression, it can be challenging for the
behavior therapist to identify behavioral targets for intervention. Second, the primary
problem of depression is often described in terms of emotions or thoughts, which can
be difficult to address behaviorally. Unlike anxiety, which involves clear avoidance
behavior, depression often does not present as overtly to the behaviorist. Thus, it is
often difficult to conceptualize the patient’s problems behaviorally. Finally, depressed
persons often have, as a primary symptom, a lack of energy and motivation to engage
in any proactive behavior. Because the essence of behavior therapy involves the
patient engaging in behaviors that will serve to alleviate her current condition, the
absence o f energy or motivation can seem an insurmountable obstacle to exacting
behavior change in the patient. These challenges not withstanding, the following
behavioral conceptualizations o f depression have been offered.
B.

F. Skinner (1953) attempted the first behavioral conceptualization of

depression wherein he introduced the notion o f depression as an extinction
1
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2
phenomenon, a concept that has been central to all behavioral positions (Lewinsohn,
1975). He achieved this by explaining depression in terms o f the functional
relationships between the interruption o f an established sequence o f responses that
have been positively reinforced by the social environment and the result of a
weakening of behavior and loneliness. While this notion advanced our understanding
of depression, it failed to provide an adequate framework within which to understand
the complexity of the relationship between the individual and the environment.
Lewinsohn (1975) identified two options for operationally defining
depression. One definition places the primary emphasis on the occurrence of specific
behaviors and explains depression as “a low rate of social behavior, verbal
expressions of guilt and personal inadequacy, sadness, etc.” (Lewinsohn, 1975,
p. 27). This strategy suggests that depressed patients can be defined in terms of
specific behavioral deficits and behavioral excesses (Lewinsohn, 1975). A second
option is to assume a common antecedent (e.g., low rate o f positive reinforcement or
learned helplessness) to be causally related to all depressions, even though the
behavioral manifestations of depression differ from one case to the next (Lewinsohn,
1975). This strategy involves examining the functional relationships between
environmental factors and behaviors in order to understand a person’s depression.
While both of these approaches are behavioral in nature, the second option provides a
more scientific model within which to conceptualize the depressive condition. In
other words, it allows for a theory or a hypothesis around which to organize what is
known about the symptoms and causes of depression. This is the basis upon which
predictions about the cure and prevention of depression can be made (Lewinsohn,
1975).
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Ferster (1973) suggested that the essential characteristic of a depressed
person is a reduced frequency of emission o f positively reinforced behavior. He
identified factors such as sudden environmental changes, punishment and aversive
control and shifts in reinforcement contingencies as giving rise to depression. In other
words, in response to one’s changing environment, a person may engage in fewer
behaviors that produce reinforcers. As a result of the reduction in reinforcer
availability, the person experiences symptoms o f depression. Ferster (1973) also
viewed failure to deal with, avoid, or escape from aversive social consequences as an
antecedent to depression. Ferster differentiated between two types o f responses to
aversive situations: direct action, which can alter the aversive situation, and indirect
activity (e.g., complaining), which simply acknowledges the aversive situation. He
described the indirect behavior as passive inasmuch as it does very little to influence
the aversive situation. The result of passive behavior is that the individual fails to act
on her/his environment in a manner that effectively eliminates or reduces the aversive
conditions), thereby strengthening depressive symptomatology.
Lewinsohn, Weinstein, and Alper (1970) contributed an important concept to
the understanding of depression. They suggested that a low rate of responsecontingent positive reinforcement is responsible for parts o f the depressive syndrome,
such as the low rate of behavior. This low rate of response-contingent positive
reinforcement is believed to evoke depressive behaviors, such as the feelings of
dysphoria, fatigue, and other somatic symptoms. Furthermore, Lewinsohn et al.
suggested that once the depressive symptoms develop, the social environment
provides contingencies in the form of sympathy, interest, and concern, which
strengthen and maintain the depressive behaviors (Lewinsohn et al, 1970). However,
because most people in the depressed person’s environment find these depressive
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behaviors aversive, they tend to avoid her as much as possible, thereby further
decreasing her/his rate of positive reinforcement and further worsening her/his
depression (Lewinsohn, 1975). This cycle makes treating depression difficult,
requiring modification of both the environment as well as the individual’s behavior to
produce change.
The total amount o f response-contingent positive reinforcement is believed to
be a function of (a) the number of events that are reinforcing for the individual, (b)
the number o f reinforcing events that can be provided by the environment, and (c) the
instrumental behavior of the individual (Lewinsohn, 1975). In other words, it is the
number of reinforcers available to the individual as well as the individual’s ability to
contact these reinforcers that determine the amount of response-contingent positive
reinforcement the individual receives, which affects the individual’s behavioral and
emotional state. Consequently, effective interventions for depression must consider
environmental as well as individual factors when targeting emotional and behavioral
changes.
The aforementioned behavioral principles offered to explain the development
and maintenance of depression have led to various behavioral treatments for
depression. Behavioral treatments have in common the goal of changing behavior
patterns in order to restore an adequate schedule of positive reinforcement for the
individual (Lewinsohn, 1975). Because of the diversity o f symptoms and the complex
learning history exhibited by each depressed individual, no single intervention
strategy is useful with all patients. Therefore, a variety of intervention techniques,
which are derived from behavioral theory, has evolved and allows the behavior
therapist to select a combination o f techniques which appear most suited for an
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individual patient (Lewinsohn, 1975). In this way, behavior therapy can be adapted to
a range of individuals with a variety of depressive presentations.
Interventions aimed at increasing the patient’s activity level are common. For
example, social reinforcement (Beck, 1970; Liberman & Raskin, 1971), token
economies (Hersen, Eisler, Alford, & Agras, 1973), and activity schedules (since
Lewinsohn et al., 1970) have been used to increase desirable behaviors in depressed
patients. Activity schedules involve the patient keeping a daily record of pleasant
activities that she performs. This technique is based on the finding that a strong
positive correlation exists between engaging in pleasant activities and mood state
(Lewinsohn & Graf, 1973; Lewinsohn & Libet, 1972). Interventions aimed at
improving depressed patients’ social skills (Lewinsohn et al., 1970) and assertiveness
skills (Wolpe & Lazarus, 1966) have been used to better enable depressed individuals
to contact reinforcers in their environment. The aforementioned interventions rest on
the theory that the social environment holds an abundance of reinforcers, but without
the proper skills, a person will be limited in her ability to access these reinforcers.
Furthermore, depressed individuals may experience social interactions as aversive and
consequently avoid social situations, thereby preventing contact with reinforcers. As
such, teaching the requisite skills greatly enhances a person’s ability to come in
contact with social reinforcers and also reduces the likelihood that a person will
experience aversive social interactions. Behavior therapists are well suited to conduct
this type o f remedial skill training with depressed individuals.
Behavior therapy has much in common with cognitive therapy and
consequently a brief review of cognitive theory and therapy o f depression wfll follow.
Beck (1963, 1964) was the first to suggest that not only are affective states
associated with cognitions, but that cognitions are responsible for depressive affective
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states. In other words, Beck argued that a thought occurs and a corresponding
emotion follows. As such, if a person’s interpretation of an experience is unpleasant,
s/he will experience a corresponding unpleasant affective response. According to this
conceptualization of depression, a person’s depressed mood is a consequence of the
individual’s attitudes and beliefs (i.e., schema), which determine how the person
interprets her experiences.
In a depressed individual, these cognitions tended to be characterized by
themes of low self-esteem, self-blame, overwhelming responsibilities, hopelessness,
helplessness, and desires to escape (Beck, 1963). Beck (1964) observed that the
more central these schema were to an individual’s existence, the more likely the
schema were to be activated in a variety of situations during times of high stress. For
example, for a nondepressed person, the belief that one is inadequate or ineffective
may arise only in situations suggesting such a conclusion (e.g., losing a job), whereas
in a depressed person, this belief may arise in a variety of situations not warranting
such a conclusion (e.g., taking longer than expected to finish a task at work). This
latter phenomenon, stimulus generalization, involves once neutral stimuli evoking a
negative cognitive response under periods o f high stress. The occurrence of these
negative beliefs is therefore not contingent upon stimuli warranting such beliefs, but
rather contingent upon high levels o f stress. As such, the goal o f cognitive therapy is
to teach the patient to examine her own thoughts and to correct for errors in thinking
when they occur (Beck, 1967). By avoiding such errors as overgeneralization,
magnification, or arbitrary inference, the depressed person is less likely to experience
depression (Beck, 1967, 1970; Beck, Rush, Shaw, & Emery, 1979).
The commonalties between cognitive and behavioral treatments for
depression may not, at first glance, seem obvious. But upon closer comparison, it
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seems clearer that the distinction between “cognitive” and “behavioral” formulations
is in terms of one’s perspective rather than in terms of operations (Taylor & Marshall,
1977). First, in both cognitive and behavioral therapy, the interview is more
structured and the therapist is more active compared in other psychotherapies (Beck,
1970). In contrast to the more traditional therapist roles of listening and reflecting,
the behavior therapist and the cognitive therapist actively formulate the patient's
presenting probIem(s) and take an active role in guiding the patient to make the
desired changes in her overt behaviors or thoughts. For example, collaborative
empiricism, wherein the therapist and the patient work together to gather evidence
and to test theories about the patient’s problems, is central to behavioral and
cognitive therapies.
Second, the therapeutic efforts of behavior therapists and cognitive therapists
are focused on the overt symptom or behavior problem, such as a particular phobia
or obsession (Beck, 1970). However, the target typically differs inasmuch as the
behavior therapist focuses on the overt behavior (e.g., avoidance response), whereas
the cognitive therapist focuses on the ideational content involved in the symptom
(e.g., the irrational inferences) (Beck, 1970). Nonetheless, it is the conceptualization
of symptom formation in terms of constructs that are accessible either to behavioral
observation or introspection that links cognitive and behavior therapy in this respect
(Beck, 1970).
A third commonality, which also is in contrast to psychoanalytic therapy, is
that neither cognitive therapy nor behavior therapy draws substantially on
recollections or reconstructions of the patient’s childhood experiences and early
family relationships (Beck, 1970). The emphasis of both approaches is on current or
recent experiences and how they relate to current functioning.
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A final commonality between behavior therapy and cognitive therapy is the
assumption that the patient has acquired maladaptive reaction patterns that can be
“unlearned” without the absolute requirement that she obtain insight into the origin of
the symptom (Beck, 1970). Through the use of behavioral principles, both overt
behaviors and cognitions are targeted to produce a reduction in depressive
symptomatology. Consequently, therapy tends to be change-focused rather insightfocused, which allows the therapist and the patient to evaluate therapy outcomes and
make stronger decisions regarding treatment.
Due to the similarities between cognitive and behavior therapies, a
convergence of the two approaches has occurred which has spawned what are
typically described as “cognitive-behavioral” therapies (e.g., Beck’s Cognitive
Therapy). As the name implies, cognitive-behavioral therapies utilize both cognitive
and behavioral principles to produce changes in overt behavior and covert cognitions.
Typically, irrational beliefs and dysfunctional behaviors are the targets for change and
interventions aimed at changing these maladaptive beliefs and behaviors are employed
by the therapist. For example, a cognitive-behavioral therapist may instruct a patient
who excessively criticizes herself to limit criticizing sessions to 60 seconds and allow
no more than five sessions per hour. In this way, behavior change occurs and
continued practice o f this strategy strengthens the new behavior.
Cognitive-behavioral therapies have been largely successful in treating
depression and therefore have been the focus o f much empirical research (see reviews
by Hollon, Shelton, & Loosen, 1991; Jacobson & Hollon, 1996). The following two
chapters will include a review of the literature relevant to behavioral and cognitivebehavioral treatments for depression and a detailed description of the experimental
methods utilized in this study. Additionally, empirical support for further research
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into behavioral treatments for depression will be presented. Finally, the logic and
rationale for this study will be explicated in terms o f its place in a developing line o f
empirical research and in terms of its practical implications for contemporary
psychology.
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CHAPTER n
REVIEW OF THE LITERATURE
The clinical effectiveness of cognitive-behavioral treatments for depression
has been well documented. Numerous studies have shown statistically significant
reductions in depression scale scores following cognitive-behavioral treatments
(Brown & Lewinsohn, 1984; Comas-Diaz, 1981; Covi & Lipman, 1987; Elkin et al.,
1989; Fuchs & Rehm, 1977; Graffj Whitehead, & LeCompte, 1986; Jacobson et al.,
1996; Kovacs, 1979; Lewinsohn, Clarke, Hops, & Andrews, 1990; Nezu & Perri,
1989; Peterson & Halstead, 1998; Rehm, Kaslow, & Rabin, 1987; Scott & Stradling,
1990; Shaw, 1976; Steuer et al., 1984; Zettle & Rains, 1989). Within this area o f
research, a number of variations on cognitive-behavioral therapy have been
empirically evaluated.
Therapies described as “cognitive” or “cognitive-behavioral” by their
investigators have been examined and found to be effective (Comas-Diaz, 1981; Covi
& Lipman, 1987; Graff et al., 1986; Jacobson et al., 1996; Kovacs, 1979; Lewinsohn
et al., 1990; Nezu, 1986; Nezu & Perri, 1989; Peterson & Halstead, 1998; Rush &
Watkins, 1981; Scott & Stradling, 1990; Shaw, 1976; Steuer etal. 1984; Zettle &
Rains, 1989). These therapies typically utilize both cognitive and behavioral
interventions to assist the client in changing thoughts and behaviors. For example,
Scott and Stradling (1990) compared depressed individuals receiving cognitive
therapy in either a group or an individual format with depressed individuals on a
waiting list. They found that individuals receiving cognitive therapy experienced a
10
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reduction in Beck Depression Inventory (BDI; Beck, Ward, Mendelson, Mock, &
Erbaugh, 1961) scores that was significantly greater than the reduction for those
individuals on the waiting list, F (l, 46) = 18.74, p —0.0001. The corresponding BDI
scores were as follows: a mean reduction of 79% for subjects receiving group
cognitive therapy, a mean reduction of 60% for subjects receiving individual
cognitive therapy, and a mean reduction of 22% for subjects in the waiting list
condition. Thus, in this depression study, subjects who received group cognitive
therapy experienced the greatest reductions in depression scale scores, followed
closely by subjects who received individual cognitive therapy. Subjects on the waiting
list who did not receive cognitive therapy experienced the least improvement in
depression scale scores.
Various studies have examined treatments for depression with a primary
emphasis on behavioral principles and interventions and they have reported favorable
results (Brown & Lewinsohn, 1984; Comas-Diaz, 1981; Fuchs & Rehm, 1977;
Jacobson et al., 1996; Kovacs, 1979; Shaw, 1976). For example, Fuchs and Rehm
(1977) evaluated the effectiveness o f a self-control behavior therapy for depression in
comparison to a nonspecific therapy and to a waiting list condition. The self-control
therapy involved subjects learning to self-monitor and self-evaluate their behavior and
to self-reinforce desirable behavior (Fuchs & Rehm, 1977). They found that a
reduction in BDI scores was greatest for subjects in the self-control condition,
F(2, 25) = 6.41, p < .006. Corresponding mean reductions in BDI scores among
groups were as follows: self-control condition, 78%; nonspecific condition, 40%; and
waiting list condition, 8%. Thus, while the passage of time produced only minimal
(i.e., 8%) reductions in depressive symptomatology, participation in the self control
therapy produced, on average, a substantial (i.e., 78%) reduction in depressive
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symptomatology. These findings support the effectiveness of self-control therapy in
treating depression.
Shaw (1976) compared the effects of behavior therapy to a waiting list in the
treatment o f depression. The behavior therapy group received treatment that included
the use of activity schedules, verbal contracts, and behavior rehearsal techniques
designed to teach communication and social reinforcement skills (Shaw, 1976). The
study reported a mean BDI score for subjects in the behavior therapy group that was
significantly lower after the 4-week treatment period than the mean BDI score for
subjects in the waiting list group after the same amount of time (t = 2.09, p < .05),
suggesting that behavior therapy was associated with a greater reduction in
depression scale scores than the waiting list. This study further supports the efficacy
o f behavioral treatments for depression by demonstrating greater antidepressant
effects from behavior therapy than from the waiting list.
Dobson (1989) conducted a meta-analysis of 28 studies employing cognitive
therapy for depression (as described by Beck, Rush, et al., 1979), which yielded
impressive results supporting the effectiveness of cognitive therapy. After analyzing
10 studies that compared cognitive therapy to either a no-treatment or a waiting list
control group, a mean effect size of-2.I5 was obtained, indicating that the average
cognitive therapy subject did better than 98% o f the control subjects (Dobson, 1989).
Comparing cognitive therapy to pharmacotherapy, eight studies yielded a mean effect
size o f-0.53, indicating that cognitive therapy subjects fared better on outcome
measures than 70% of drug therapy subjects (Dobson, 1989). The results o f this
meta-analysis strongly suggest that cognitive therapy is more effective for treating
depression than no therapy at all. Furthermore, based on this meta-analysis, cognitive
therapy appears to be at least as effective as drug treatment for treating depression,
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given that subjects who receive cognitive therapy tend to achieve outcome measure
scores as low as, or lower, than subjects receiving medication.
While the aforementioned studies suggest that cognitive-behavioral
treatments for depression are effective, they do not provide a clear understanding of
which components in the treatment packages are the active ingredients responsible
for therapeutic change. In order to isolate the mechanisms of change that are either
necessary or sufficient to produce the desired effects, an examination o f cognitivebehavioral therapy and its components was performed with the goal of teasing apart
the essential factors from the unessential factors. Jacobson and his colleagues (1996)
conducted this dismantling study to dissect and examine Beck’s Cognitive Therapy
(CT) for depression (Beck, Rush, et al., 1979).
In the study, the efficacy of the strict behavioral component, referred to as
Behavioral Activation (BA), the BA plus modification o f automatic dysfunctional
thoughts component (AT), and the full cognitive-behavioral treatment (CT) were
compared. Subjects in each treatment condition received the prescribed treatment
over the course of 16 weeks with a maximum of 24 sessions. Depression was
measured before the onset of therapy, at the time of termination, and at 6-, 12-, 18-,
and 24-month follow-ups using the Beck Depression Inventory and the Hamilton
Rating Scale for Depression (HRSD; Hamilton, 1960), both of which measure
depressive thoughts, behaviors, and emotions. Data analysis revealed no significant
differences, F(4, 252) = 1,p > .05, between treatment conditions in terms o f levels of
depression at treatment termination (Jacobson et al., 1996). Furthermore, there were
no significant differences between treatment conditions in terms of depression scale
scores at the 6-month follow-up, F(2,132) < l , p > .05; the 12-month follow-up,
F(2, 136) < 1, p > .05; the 18-month follow-up, F(2, 133) < l , p > .05; or the 24-
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month follow-up, F(2,128) > 1, p > .05 (Gortner, Gollan, Dobson, & Jacobson,
1998).
As such, it was concluded that CT was no more effective than either of its
components in treating depression (Jacobson et al., 1996). In other words, subjects
who received BA alone improved as much as those who received additional
interventions specifically aimed at modifying cognitive structures, underlying
assumptions and core schema. Thus, it was suggested that Behavioral Activation
alone may be a sufficient treatment for depression, producing antidepressant effects
equivalent to those produced by cognitive therapy.
These findings have two potentially valuable implications for the
understanding and treatment of depression. First, the findings suggest that
interventions focused explicitly on altering thinking may not be necessary to alter
depressive thoughts and beliefs. Instead, the exposure to naturally reinforcing
contingencies may produce changes in thinking equally as effective as the expressly
cognitive interventions (Jacobson et al., 1996). Second, because BA is a more
parsimonious treatment than CT, BA may be more amenable to less costly
alternatives to (individual) psychotherapy (Jacobson et al., 1996).
The Jacobson et al. (1996) study is of strong scientific value, particularly in
light of the recent drive for empirical support for psychological treatments. The use
of validation criteria to evaluate treatments has spawned scholarly writings
concerning what the concept truly means and how it should be utilized by the
scientific community. Borkovec and Castonguay (1998) state that therapy research,
as an experimental science, is capabile of establishing cause-and-effect relationships
and nothing more. Furthermore, statements about empirical support for a therapy
technique must be clearly made with reference to the only defensible conclusion: The
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investigated therapy caused some improvement beyond chance and factors common
to all therapeutic relationships or beyond such factors as the passage of time and
repeated testing (Borkovec & Castonguay, 1998).
To achieve the goal o f empirical support, research must be addressed at both
a theoretical and a concrete level. At the theoretical level, this requires generating
rival hypotheses, designing experiments that will rule out one or more of those rival
hypotheses, conducting a clean experiment, and recycling these steps on hypotheses
that remain unrejected (Borkovec & Castonguay, 1998). At the concrete level, this
entails using dismantling, constructive, and parametric designs whose very processes
lead to the identification of increasingly specific cause-and-effect relationships
(Borkovec & Castonguay, 1998). Understanding depression and its treatment will
come from research that preserves these ideals.
The Jacobson et al. (1996) study utilized a dismantling design, which
produced results that provide a clearer understanding of the cause-and-effect
relationships between cognitive therapy (and its components) and depression than has
been reported. Thus, through the use of a design strategy with a primary goal of
identifying causal factors contained in a treatment package, Jacobson et al. (1996)
identified the BA component as an active ingredient in cognitive therapy, producing
clinically significant antidepressant effects worthy o f further experimental
manipulation.
After achieving the primary goal o f establishing that cognitive-behavioral
treatments for depression are clinically effective, it is now appropriate to examine
what could be referred to as “nonclinical” goals involved m the delivery of mental
health services. With the recent emergence of managed health care, cost-effectiveness
o f treatment has become a heightened concern o f both those providing and those
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paying for mental health services. This issue is addressed nicely by Chambless and
Hollon (1998) in their statement that

.. all things being equal, those treatments that

cost the least are likely to be preferred if there is no great difference in outcome”
(p. 16). It appears that the time has come to uncover those treatments that are both
clinically effective and economically efficient.
Under the control of managed care, many managed health-care programs
contain a managed behavioral health-care component, or mental health and substance
abuse is “carved out” to another company that specializes only in behavioral care.
Despite the form of these programs, all emphasize brief and time-effective modes of
mental health treatment (Budman, 1996). Among the time-effective modes of
treatment, group therapy appears to be a promising option, both economically and
clinically.
Economically, the use of time-limited and ongoing group therapy can
meaningfully decrease the percentage of staff time devoted to nonemergent care,
thereby creating significant savings (McKenzie, 1996). One approach to examining
the efficiency of group psychotherapy is to assess the costs to the patient, the
provider, and the third party payer and to compare the costs with corresponding
costs of a similar treatment, such as individual psychotherapy. Toseiand and Siporin
(1986) reviewed the group therapy literature with this purpose in mind and identified
12 studies that included both group and individual therapy. Ten of the 12
investigators concluded that group therapy was more efficient than individual therapy
(Toseiand & Siporin, 1986).
Piper and Joyce (1986) compared the efficiency of short-term group therapy
with short-term individual therapy, as determined by the amount of time required by
patient and therapist. For both group and individual therapy, treatment consisted of
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24 sessions over a 6-month period. Group therapy (consisting of eight patients)
lasted 1.5 hours per session; individual therapy was provided in sessions that lasted
0.9 hours. From the therapist’s perspective, short-term group therapy, which required
4.5 hours per patient, was more efficient than short-term individual therapy, which
required 21.6 hours per patient, representing a time ratio of 1:5 (Piper & Joyce,
1986). In contrast, from the patient’s perspective, short-term individual therapy,
which required 21.6 hours, was more efficient than short-term group therapy, which
required 36 hours, with a time ratio of approximately 1:2 (Piper & Joyce, 1986).
These figures suggest that for the patient, group therapy requires almost twice the
time commitment, whereas the therapist can treat about five times as many patients in
group therapy as she can in individual therapy. Thus, for the therapist and the third
party payer, short-term group psychotherapy appears to greatly reduce time demands
and financial costs, while the patient endures longer time demands but potential
decreases in costs.
Clinically, the primary question that is asked about group psychotherapy is
whether it is as efficacious as individual therapy (Piper & Joyce, 1996). In a review of
over 200 studies that included both group and individual therapy, the average effect
size for group therapy was found to be 0.83 and the average effect size for individual
therapy was nearly equivalent at 0.87 (Smith, Glass, & Miller, 1980). These effect
sizes suggest that both individual therapy and group therapy produced significant
changes in outcome measures. As such, this review provided answers of “yes” to
both questions concerning the general efficacy o f group psychotherapy (Piper &
Joyce, 1996).
Piper and Joyce (1996) reviewed studies from 1983 through 1994 that
involved the use o f time-limited, short-term group therapy. O f the 50 studies that
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included a time-limited group therapy versus control comparison, 48 provided
evidence o f significantly greater benefit for the therapy condition (Piper & Joyce,
1996). O f the sue studies that included a time-limited group therapy versus an
individual therapy comparison, only one provided evidence o f superiority for the
group therapy and only one provided evidence of superiority for the individual
therapy (Piper & Joyce, 1996). Based on these findings, they concluded that there
was clear evidence of clinical benefit for time-limited, short-term psychotherapy of
different theoretical and technical orientations across a diverse range o f patients, and
o f approximately equivalent effects for group and individual therapy (Piper & Joyce,
1996). Consequently, pursuit of group therapy treatments appears to be clinically
indicated.
Combining this focus with a focus on depression provides a framework within
which to evaluate group therapy’s effectiveness for treating depression. Various
studies from the past two decades have provided support for cognitive-behavioral
group treatments for depression (Brown & Lewinsohn, 1984; Comas-Diaz, 1981;
Covi & Lipman, 1987; Free, Oei, & Sanders, 1991; Fuchs & Rehm, 1977; Graff
et al., 1986; Lewinsohn et al., 1990; Nezu, 1986; Nezu & Perri, 1989; Peterson &
Halstead, 1989; Rehm et al., 1987; Rush & Watkins, 1981; Scott & Stradling, 1990;
Shaw, 1976; Steueretal., 1984; Zettle & Rains, 1989).
Recently, Peterson and Halstead (1998) evaluated the effectiveness of a group
cognitive-behavioral therapy for depressed persons in a community setting. They
utilized Depression Management Group (DMG), a manualized treatment program
oriented toward helping patients learn skills to reduce or eliminate depression
(Peterson & Halstead, 1998). The treatment consisted of 2-hour sessions held weekly
for 6 weeks, with groups ranging from 6 to 12 members. Session content focused on
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increasing pleasurable activities, problem solving, identifying and understanding the
effects of cognitive distortions, and disputing irrational cognitions. At termination of
the 6-week program, there was a statistically significant reduction, F (l, 274) =
108.74, p < .001), in mean depression scale scores for all participants (N= 138)
(Peterson & Halstead, 1998). Peterson and Halstead (1998) concluded that DMG
therapy for depression was a clinically effective treatment approach when
administered in a community setting. The results of the study provided support for
the effectiveness of cognitive-behavioral group therapy with depressed individuals in
community settings.
Brown and Lewinsohn (1984) evaluated the effectiveness of a group
psychoeducational approach to treating depression with a commitment to a social
learning theory of depression and to providing instruction in basic self-change skills.
The authors reported a course of treatment, consisting of 12 sessions over an 8-week
period, that produced statistically significant reductions in BDI scores compared to
patients in the waiting-list condition, F (l, 61) = 4.0, p < .05). They concluded that
the psychoeducational approach administered in a group format could be an effective
treatment for depression (Brown & Lewinsohn, 1984). The aforementioned studies
suggested that group cognitive-behavioral therapies could be effective in the
treatment of depression.
The literature involving time-limited short-term psychotherapy suggests that it
is a valuable alternative to individual psychotherapy, achieving nearly equivalent
therapeutic outcomes as well as surpassing individual psychotherapy in terms of
conservation of resources. Based on these data, there is evidence to support research
oriented toward transforming BA into a time-limited short-term group psychotherapy
treatment. If BA could be delivered in a group therapy format and achieve clinically
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significant (Jacobson & Truax, 1991) effects in a similar amount of time to that which
is required for BA individual therapy, then it is likely that BA group therapy will be a
more cost-effective alternative than individual therapy for the treatment of
depression.
With this supposition in mind, the experimental questions addressed by this
study were:
1.

Could Behavioral Activation Group Therapy (BAGT) be administered to

be more clinically effective than a wait-list control condition for treating depression?
3. Could BAGT produce therapeutic effects similar to those produced by BA
individual therapy? Consequently, the goals o f this study were to administer
Behavioral Activation Group Therapy (BAGT) to individuals in community settings
suffering from clinical depression and to demonstrate the effectiveness of BAGT by
obtaining significantly reduced BDI-II and RHRSD scores for BAGT subjects
compared to waiting-Iist subjects.
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CHAPTER m
METHOD
Sample
Forty-two adult patients seeking mental health services for unipolar
depression at four Southwestern Michigan community mental health (CMH) agencies
(Barry County, Berrien County, Calhoun County, and Van Buren County) qualified
for inclusion in the study. These agencies primarily serve rural populations. Four
subjects dropped out o f the study before beginning treatment, while another 4
subjects began treatment but dropped out before completing the minimum number of
required sessions. The remaining 34 subjects fulfilled the requirements of their study
condition, thereby generating viable outcome data. Nine subjects participated at Van
Buren County CMH, 12 subjects participated at Barry County CMH, 10 subjects
participated at Calhoun County CMH, and 3 subjects participated at Berrien County
CMH.
Subjects met criteria for Major Depressive Disorder (MDD) according to the
Diagnostic and StatisticalM anual o f M ental Disorders-Fourth Edition (DSM-IV)
(American Psychiatric Association, 1994). DSM -IV diagnoses were based on the
Structured Clinical Interview for DSM -IV (SCID) (First, Spitzer, Gibbon, &
Williams, 1997). Subjects scored at least 20 on the Beck Depression InventorySecond Edition (BDI-II) (Beck, Steer, & Brown, 1996), and 14 or greater on the
first 17 items of the Revised Hamilton Rating Scale for Depression (RHRSD)
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(Warren, 1996). Doctoral students in a clinical psychology graduate program
performed screening interviews. Training and supervision of the SCID and the
RHRSD were provided by the author and included use o f the SCID training videos
and the RHRSD manual.
Exclusion criteria included a number of concurrent psychiatric disorders (i.e.,
bipolar or psychotic subtypes of depression, panic disorder, current alcohol or other
substance abuse, past or present schizophrenia or schizophreniform disorder, organic
brain syndrome, and mental retardation). The comorbid presence of a personality
disorders) did not influence decisions regarding participation in the study. Suicide
status was assessed; however, no subjects were excluded from the study due to their
suicide status. Once treatment began, suicide status was assessed on an ongoing basis
by the treating clinician(s) using the BDI-II. No subjects were removed from the
study based on these ongoing assessments.
After qualifying for the study, participants were required to wait from 1 to 45
days to begin treatment. The length of this waiting period represented the latency
between the date of the participant’s screening interview and the date at which the
next BAGT group was scheduled to begin at the CMH agency. The length of this
waiting period determined each subjects classification as either a “wait-list” subject or
a “treatment” subject. Those participants who waited 28 days or longer to begin
treatment were considered “wait-list” subjects, while those participants who started
treatment within 28 days of the initial screening were considered “treatment”
subjects. All treatment groups were closed groups that did not allow the addition of
group members after the first session o f treatment.
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Therapists
Eight therapists, two from each agency, delivered the treatment. All therapists
held either a Masters degree or a Doctoral degree in psychology or social work and
were licensed to deliver mental health services in the state o f Michigan. Therapists
received 12 hours of training in the use of Behavioral Activation Group Therapy
(BAGT) for depression. Richard Spates, Ph.D., and Jeffrey Porter, M.A., conducted
the training. The theory and practice of BAGT was based heavily upon the
Behavioral Activation manual developed by Jacobson et al. (1997), which was
derived from Beck’s original Cognitive Therapy manual (Beck, Rush, et al., 1979).
Jacobson et al.’s (1996) BA manual included specific guidelines for interventions that
were prescribed (i.e., behavioral interventions), as well as for interventions that were
proscribed (e.g., cognitive interventions). The adaptation of BA to a group therapy
format was completed by the investigators of the current study with a Behavioral
Activation Group Therapy manual developed to guide treatment. The BAGT manual
is a “hands on” manual that was written for clinicians who did not have a strong
background in behavioral psychology.
Treatment
The behavioral view explains depression in relation to three factors (Jacobson
et al., 1997). The first factor is a predisposition to depression and is referred to as the
vulnerability factor. Vulnerability suggests that not all persons are equally at-risk for
developing depression. Recognition that a vulnerability to depression exists stems
from the observation that not all people who experience similar life circumstances or
who have similar genetic make-ups develop depression. Consequently, it is theorized
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that vulnerability is multiply determined by a person’s genetics and by a person’s
learning history. Vulnerability explains why some people get depressed when a
certain life event occurs and why others do not when experiencing the same life
event. For example, the termination of a significant relationship may evoke a
depressive response from some individuals, while others may navigate the experience
without a depressive reaction.
The second factor relates to the development of a depressive episode. This
factor posits that depression results when changes in a person’s life circumstances
produce a reduction in reinforcement. These changes can take the form of major life
events, such as the loss of a loved one or the termination o f a significant relationship,
which can dramatically disturb an established schedule of reinforcement. These
changes also can take the form o f daily hassles and a chronically stressful
environment, which can restrict opportunities for pleasurable and/or meaningful
experiences. Essentially, any set o f life circumstances that prevents an individual from
contacting reinforcers is sufficient to promote the development of a depressive
episode in a vulnerable individual.
The third factor is the maintenance factor and it explains why depression, if
left untreated, tends to persist. The maintenance of depression is posited to be
determined by the way an individual copes with her depression. Behavioral theory
suggests that once a person becomes depressed, her ways o f responding to her
depression often deprives her of further reinforcement, thereby maintaining and often
times making the depression worse (Jacobson et al., 1997). Thus, negative
experiences, chronic stressors, and daily hassles trigger depression to develop in
vulnerable persons; the individual’s method o f coping, which often tends to be self-
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defeating by generating fewer opportunities for reinforcement, maintains the
depression and may cause it to worsen.
Based on this conceptualization of how depression develops and how it is
maintained, the overall purpose of BA treatment for depression is to: (a) determine
the life circumstances that have precipitated the depression, (b) determine the coping
patterns that have exacerbated the depression, and (c) develop a treatment plan for
improving the coping patterns and for providing access to more reinforcing life
circumstances (Jacobson et al., 1997). This goal can be achieved through the use of
various behavioral interventions, including but not limited to (a) monitoring o f daily
activities; (b) assessment of the pleasure and mastery that is achieved by engaging in
a variety of activities; (c) assignment of increasingly more difficult tasks that have, as
their goal, the attainment of a sense of pleasure or mastery; (d) cognitive rehearsal of
scheduled activities, in which participants imagine themselves engaging in various
activities with the intent of finding obstacles to the imagined pleasure or mastery
expected from those events; (e) discussion of specific problems and the prescription
. of behavior therapy techniques for dealing with them; and (f) interventions to
ameliorate deficits in social skills (e.g., assertiveness training, communication skills)
(Jacobson et al., 1996, 1997).
The current study sought to extend the work of Jacobson et al. (1996) by
examining BA delivered in a group therapy format. BAGT employed two co
therapists leading a group o f 6 to 10 patients. Co-therapists were responsible for
reviewing BDI-Us at the beginning o f each session, leading group discussions
focused on Behavioral Activation principles, soliciting group member feedback,
planning and evaluating interventions, and providing feedback to group members.
BAGT sessions lasted for 95 minutes and occurred weekly for a 10-week period.
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The 10-week course of treatment employed in this study differed from the 16week course o f treatment used by Jacobson et al. (1996). The length o f treatment
was determined by a review of recent studies o f cognitive-behavioral treatment for
depression. Based on 24 studies reviewed by Dobson (1989) that involved treatments
described as “cognitive,” “behavioral,” or “cognitive-behavioral,” the mean course of
treatment was 10.04 weeks, with a median o f 10 weeks and a range of 4 to 20 weeks.
Moreover, the BA treatment duration o f 16 weeks utilized by Jacobson et al. (1996)
was employed to provide consistency, in terms of duration of treatment with CT,
which is prescribed by Beck, Rush, et al. (1979) as a 16-week treatment. Thus, in an
effort to develop an increasingly cost-effective treatment for depression and due to a
lack of contraindications for a briefer version of BA, a treatment duration of 10
weeks was used.
A wait-list control (WLC) condition was used to assess the effects of
repeated assessment, the effects of passage of time, and, in some cases, the effects of
concurrent pharmacological or psychological treatment for depression. Subjects
classified as WLC subjects were informed that treatment was not available at the time
o f screening. Additionally, they were told that as soon as a new group formed, they
would receive a 10-week course of BAGT treatment. WLC subjects waited 4 to 6
weeks to begin BAGT treatment. Subjects in this condition were asked not to initiate
any new treatment for depression while waiting for BAGT treatment However, these
subjects also were told that if their depression worsened and warranted emergency
treatment, that they should contact their CMH agency therapist or caseworker.
The use of a wait-list control condition strengthened our knowledge of the
relationship between BAGT and therapeutic change. By including a 4- to 6-week
waiting period, spontaneous remission o f depression, if it occurred, could be
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detected. Additionally, because many subjects were receiving some concurrent form
of treatment for depression during the waiting period, the data would reflect any
changes in depressive symptomatology resulting from other treatments. Thus, if
subjects in the WLC condition experienced significant reductions in depression scale
scores during the 4- to 6-week waiting period, this would suggest that their
depression remitted as a result of the passage of time or assessment, or that their
current treatment regimen was adequate to produce a significant reduction in
depression. However, if depression measures for those individuals in the WLC
condition did not change significantly during the 4- to 6-week period, this would
suggest that their depression did not spontaneously remit or come under the control
of other treatments). Furthermore, if those subjects then received BAGT and
subsequently experienced significant reductions in depressive symptoms, then a
strong argument for BAGT as the mechanism o f change could be made.
The use of a community mental health population represented another point
of departure from the original study (Jacobson et al., 1996). BA was shown to be
efficacious for persons with depression in a controlled laboratory environment
(Jacobson et al., 1996). While such empirical support is indeed valuable, it is essential
to “conduct scientifically valid therapy research in the applied setting, both to address
the generalizability issue and to generate meaningful results o f long-lasting value”
(Borkovec & Castonguay, 1998, p. 139). To achieve this end, BAGT was
administered and assessed in natural CMH settings.
Evaluation of BAGT in a natural setting introduced a problem with respect to
the concurrent use of psychotropic medication and BAGT. Specifically, many
subjects (i.e., 79%) were receiving pharmacotherapy for depression prior to entering
the study. This concurrent use o f treatments had the potential to confound
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interpretation o f the outcome data (i.e., identification of causal agent[s]). As such, a
decision to exclude patients on this basis was considered. Because BAGT was
assessed in a natural environment, it was deemed important to preserve the
conditions o f the environment. To exclude those patients on medication from the
study would be antithetical to the reason for conducting such naturalistic research.
Therefore, the concomitant use of psychotropic medication(s) with BAGT was
permitted. However, in order to control for the effects of pharmacotherapy and to
minimize the effects o f a changing pharmacology regimen, the following guidelines
were followed: Patients who were taking psychotropic medication(s) at the onset of
BAGT were (a) required to be on a maintenance dose of the medication for a
minimum of 6 weeks prior to participating in the study, and (b) asked not to change
their medication use during the course of BAGT treatment. This included changing
dosages, terminating medication use and/or starting a new medication. Patients who
were not using psychotropic medication(s) at the onset of BAGT treatment were
asked not to start psychotropic medication use while receiving BAGT treatment.
Subjects were asked questions about their medication use at screening, at treatment
termination, and at follow-up; data on medication use were based on these responses.
Outcome Measures
All participants who completed treatment were evaluated for depression
(a) before treatment began, (b) at the termination of treatment, and (c) at 3 months
following the termination of treatment. The BDI-II and the RHRSD were used to
assess depressive symptomatology. Additionally, the SCED was administered at all
three assessment times to assess for the presence of Major Depressive Disorder.
Assessing subjects in terms of whether or not they met diagnostic criteria for major
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depression at treatment termination and follow-up provided another means of
evaluating clinical significance, equating a change in diagnostic status with clinically
significant change. Subjects also were given the BDI-H at every therapy session
during the course of treatment to monitor change on a weekly basis.
For subjects assigned to the WLC condition, assessment with the BDI-H
occurred at the beginning and at the end of the 4- to 6-week waiting period. These
assessments served as the precondition and postcondition data. Once the waiting
period ended and subjects began BAGT, WLC subjects were assessed on the same
schedule as treatment condition subjects. This was done in order to assess the effects
of BAGT for the wait-list subjects.
The Beck Depression Inventory (BDI) is a widely used self-report measure of
depression severity that has excellent psychometric properties (Beck, Steer, &
Garbin, 1988) and is sensitive to clinical change (Edwards et al., 1984; Lambert,
Shapiro, & Bergin, 1986). It has recently been revised into the BDI-II (Beck, Steer,
& Brown, 1996) to be consistent with DSM -IV diagnostic criteria for Major
Depressive Disorder. The BDI-H, like the original BDI, contains 21 items scored on
a 4-point Likert scale that assess cognitive, affective, somatic, and vegetative
symptoms of depression. Unlike the original BDI, which assesses depressive
symptomatology during the preceding week, the BDI-II requires reporting about
symptoms occurring within the preceding 2 weeks. Item scores are added to come up
with a final score. Beck, Steer, and Brown (1996) have suggested the following
guidelines for interpreting total BDI-H scores in persons with depression: 0-13,
minimal depression; 14-19, mild depression; 20-29 moderate depression; 30-63
severe depression. According to Beck, Steer, and Brown (1996), “The transition
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from the usage of the BDI to that of the BDI-H should introduce no meaningful
interpretative problems” (p. 17).
Psychometric evaluations have supported the BDI-II as a valid and reliable
measure of depression (Steer, Ball, Ranieri, & Beck, 1997). In a study utilizing 944
outpatient subjects collected from six samples, alpha reliability coefficients on the
BDI-II ranged from .79 to .90 (Beck, Steer, Ball, & Ranieri, 1996). This suggests
that variance in scores is primarily due to true variation and not to error. The
reported internal consistency was .92, and test-retest reliability was .93 for
psychiatric outpatients (Beck, Steer, Ball, et al., 1996). This suggests that the items
contained in the BDI-II are strongly consistent with one another and that repeated
administration of the BDI-II one week after the initial administration produces similar
results.
Comparing the BDI-II with the BDI in psychiatric outpatients produced a
correlation of .93 (p < .001), which suggests that the BDI-II possesses good
concurrent validity. Furthermore, the BDI-II was found to be positively correlated
(p < .001) to the Beck Hopelessness Scale (Beck & Steer, 1988) (r = .68) and the
Scale for Suicidal Ideation (Beck, Kovacs, & Weissman, 1979) (r = .37), two scales
which have been reported to measure the construct of depression. This evidence
further suggests that the BDI-II measures the construct o f depression as it purports.
The Revised Hamilton Rating Scale for Depression (RHRSD) is a revision of
the Hamilton Rating Scale for Depression (HRSD), which was originally designed by
Hamilton (1960) as a rating scale for clinicians to use with individuals already
experiencing a depressive illness. The scale consists of 22 items that assess
behavioral, somatic, cognitive, and emotional symptoms o f depression. The first 17
items on the RHRSD are the original items from the HRSD and were used to
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represent RHRSD scores in this study. Utilizing only the first 17 items permitted
closer comparisons with other outcome studies that used the original HRSD (e.g.,
Jacobson et al., 1996).
Psychometric evaluations of the RHRSD have supported its use as a reliable
measure of clinical depression (Warren, 1996). Internal consistency for the
verification sample was estimated at .79 (Warren, 1996), suggesting that there is a
high degree o f consistency among items within the RHRSD. Because the RHRSD is
a clinician rating form, interrater reliability is o f particular importance. Estimates of
interrater reliability for the original HRSD ranged from .52 to .96 (Hedlund &
Vieweg, 1979). This level of interrater reliability is quite good considering the nature
of clinical judgment.
Correlations between the HRSD and other measures o f clinical depression
support the validity of the HRSD. Hedlund and Vieweg (1979) reported an average
correlation o f .67 with the BDI (23 studies), and .48 with the Depression subscale of
the Minnesota Multiphasic Personality Inventory (MMPI) (4 studies). The BDI and
MMPI are two well-established clinical instruments, and these findings support the
HRSD’s validity for measuring depressive symptoms. Overall, the HRSD has been a
widely accepted and widely utilized measure of depression by researchers and
clinicians alike; the subtle changes contained in the RHRSD provide little reason for
questioning its utility for these purposes.
Procedure
Subjects for the study were recruited within the participating CMH agencies.
This was accomplished by CMH staff referring potential subjects to the BAGT
therapists in house. Additionally, any new CMH clients were assessed by BAGT
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therapists for inclusion in the study. Once identified, the client was given a BDI-H to
complete and this was scored by the CMH agency clinician. If the client met the
criteria o f scoring 20 or greater on the BDI-II, the client was given a brief vocal
description of the study and the treatment; the client was asked if she would like to
find out more about the study. If the client was interested, the CMH agency clinician
contacted the principal researcher and a screening interview was scheduled.
When potential subjects arrived at the CMH agency for the screening
interview, they were given a consent form (Appendix B) and asked to read and sign
it, if agreeable. If they consented to participate in the study, they were assigned a
research code number, which was used on all subsequent research forms and the
interviewer screened them at that time. Screening involved administration of a
demographic questionnaire (Appendix C), a BDI-II (Appendix D), a RHRSD
(Appendix E), and a SCID (available upon request). At the conclusion of the
screening, the interviewer was available to answer questions the participant had
regarding the questionnaire or any of the assessment instruments. The participant was
told that she would be contacted within 7 days regarding her qualification for the
study. Each participant who qualified for the study was given a group therapy version
of Copingwith Depression: A M anualfo r Self-Help (Jacobson et al., 1997) that was
written by the principal investigator. The interviewer scored the SCID and the
RHRSD and filed them, along with the demographic questionnaire and the BDI-II, in
a designated folder. The participant’s consent form was filed in a separate folder
identified for this purpose.
A secure filing system was established at each agency that contained a folder
for each subject participating in the study. AH research data for each subject were
stored in her/his respective folder. This was done to protect the confidentiality o f the
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research data. Providing and maintaining these filing systems was the responsibility of
the researchers. A master list (Appendix F) was created at each agency to ensure
subject confidentiality and was the only link between subjects and their research code
numbers. A universal data collection form (Appendix G) was used to record all
assessment information for each subject. The master lists and consent forms were
stored in locked files separate from the demographic questionnaires, data collection
forms, BDI-IIs, RHRSDs, and SCIDs. Progress notes and other agency-related
treatment documentation for subjects in this study were kept separate from the
research data and were managed by the treating agency.
Participants not meeting the criteria for inclusion were telephoned by the
CMH agency BAGT clinician, informed o f their status, and offered services in a
fashion consistent with the standard practice of the agency. Those meeting criteria for
inclusion in the study were telephoned by the CMH agency BAGT clinician and
invited to participate. Upon acceptance to participate, subjects were given the start
date of their treatment, if available, or told that they would be contacted as soon as a
start date was established. The scheduling of therapy sessions was the responsibility
o f the participating agency. A BAGT group could begin when at least 6 subjects had
been assigned to the group.
BAGT sessions occurred weekly for 10 weeks. Each session lasted 95
minutes and all scheduling decisions were made by the co-therapists and their
respective agency. Before each therapy session, all subjects were asked to complete a
BDI-H. Weekly BDI-IIs were collected by the co-therapists and placed in each
subject’s folder.
At the end o f the 4- to 6-week waiting period, subjects in the WLC condition
were offered BAGT. They were again assessed with the BDI-IL These subjects
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received BAGT weekly for 10 weeks in a fashion that was identical to the treatment
condition subjects.
At the termination of treatment, assessments with the BDI-II, the RHRSD,
the SCID, and the Treatment Termination Questionnaire (Appendix H) were
conducted by an independent assessor. These assessments were completed either in
person at the CMH agencies or by telephone, as many subjects were unable to
arrange transportation to the agency; the assessments were filed with all previous
assessments in the appropriate folder. Subjects were reminded that they would be
contacted in 3 months for another assessment of their depression. At 3-month followup, subjects were contacted and the assessment was performed over the phone. The
interviewer again administered the BDI-II, the RHRSD, the SCID, and the Follow-up
Questionnaire (Appendix I) and placed these documents in the patient’s folder. At
this point, all assessments were complete and the subject’s folder was closed.
Subjects were thanked for their participation in the study and informed that their
involvement in the study was complete.
Upon completion o f the data collection, research folders and the contents
from all four agencies were moved to the office of the principal investigator, where
they will remain, along with the consent forms, in a locked cabinet for a period of 3
years; they will then be destroyed.
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CHAPTER IV
RESULTS
Analysis Plan
A pretest-posttest design with wait-list control was used to assess for
differences in BDI-H scores between subjects in the treatment condition and subjects
in the wait-list condition. This was achieved using independent samples t tests
comparing mean BDI-II scores at posttreatment and follow-up for subjects in the
treatment condition to mean BDI-II scores at postwaiting period for subjects in the
wait-list condition. A significant group difference in BDI-II scores was the
hypothesized outcome. The second set of primary analyses was an examination of
outcome measures across time for all subjects who completed BAGT. This was
possible because all subjects, including those in the wait-list condition, received the
same treatment. These analyses were achieved using paired-sampies t tests with BDIII and RHRSD scores as the dependent variables. Intent-to-treat analyses also were
performed on the entire sample to control for dropouts.
Additionally, the data were separated by site and analyzed to determine
whether differential effects o f treatment occurred as a function o f the site where
therapy was delivered. Such allegiance effects were suggested in at least one previous
study (Elkin et al., 1989) employing multiple treatment sites which imposed serious
interpretative problems (Jacobson & Hollon, 1996). Examination of the effects o f
medication on subject response to BAGT was performed utilizing independent
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samples t tests with medication status as the independent variable and BDI-II and
RHRSD scores as the dependent variables.
Preliminary Analyses
Table 1 displays demographic information for the entire sample. Of the 42
subjects who entered the study, 38 were women and 4 were men. Thirty-seven of the
subjects identified themselves as “Caucasian,” while 3 identified themselves as
“American Indian” and 2 identified themselves as “African American.” At the time of
the initial screening, 12 reported their relationship status as “married,” 14 reported
their status as “divorced,” and 9 reported their status as “separated.” The remaining 7
subjects reported their status as either “widowed,” “living with a significant other,”
or “single, never married.” In terms of education level, 12 subjects reported “more
than 12 years and less than 16 years of education,” 14 reported “ 12 years or a GED,”
and 11 reported “less than 12 years o f education.” The remaining 5 subjects reported
either “16 years of education” or “more than 16 years of education.” Finally, 15 of
the subjects reported their household income as “less than $10,000 per year,” 12
reported “$10,000 to $20,000 per year,” 11 reported “$20,000 to $30,000 per year,”
and 4 reported “$30,000 to $50,000 per year.”
Background data were collected on subjects that specifically related to their
mental health history. Twenty-five subjects entered the study with a diagnosis of
Major Depressive Disorder, Recurrent, while another 8 subjects entered the study
with diagnoses of Major Depressive Disorder, Recurrent and Dysthymic Disorder.
Seven subjects entered the study with a diagnosis o f Major Depressive Disorder,
Single Episode, while assessors were unable to determine whether the current Major
Depressive Disorder was a first episode or part o f a recurrent depression for the
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Table 1
Demographic Variables for Total Sample and by Condition
Variable

Total Sample
Qt = 42)

Gender
Male
Female

4
38

(9.5%)
(90.5%)

TX Group
(n = 13)
4 (30.8%)
9 (69.2%)

44.0

Mean Age

WL Group
(n = 29)
0
(0.0%)
29 (100.0%)

46.2

42.9

Ethnic Group
African American
American Indian
Caucasian

2
3
37

(4.8%)
(7.1%)
(88.1%)

I
I
11

(7.7%)
(7.7%)
(84.6%)

I
2
26

Relationship Status
Divorced
Living w/significant other
Married
Separated
Single, never married
Widowed

14 (33.3%)
3
(7.1%)
12 (28.6%)
9 (21.4%)
2
(4.8%)
2 (4.8%)

3
0
5
2
I
2

(23.1%)
(0.0%)
(38.5%)
(15.4%)
(7.7%)
(15.4%)

11 (37.9%)
3 (10.3%)
7 (24.1%)
7 (24.1%)
1 (3.4%)
0
(0.0%)

Years of Education
Less than 12
More than 12 & less than 16
12 years of GED
16 years
More than 16 years

II (26.2%)
12 (28.6%)
14 (33.3%)
2 (4.8%)
3 (7.1%)

5
6
0
0
2

(38.5%)
(46.2%)
(0.0%)
(0.0%)
(15.4%)

6
6
14
2
1

(20.7%)
(20.7%)
(48.3%)
(6.9%)
(3.4%)

Household Income
Less than $10,000 peryear
$10,000 to $20,000 peryear
$20,000 to $30,000 peryear
$30,000 to $50,000 peryear

15 (35.7%)
12 (28.6%)
11 (26.2%)
4 (9.5%)

4
4
3
2

(30.8%)
(30.8%)
(23.1%)
(15.4%)

11
8
8
2

(37.9%)
(27.6%)
(27.6%)
(6.9%)

(3.4%)
(6.9%)
(89.7%)

Note. TX = treatment; WL= wait-list.
remaining 2 subjects. When asked to describe any existing treatment for depression at
the time of the initial screening, 19 subjects reported receiving both medication and
individual therapy for depression, while 7 subjects reported receiving only individual

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

38

therapy for depression, and 4 subjects reported receiving only medication treatment
for depression. The remaining 12 subjects reported receiving some combination of
medication and (a) group therapy, (b) individual therapy, (c) case management, or
(d) pastoral care.
With respect to previous episodes of treatment for depression, 10 subjects
reported that they had not received treatment for depression prior to their current
episode. Eleven subjects reported that they had received one previous episode of
treatment for depression, 6 subjects reported two previous episodes of treatment for
depression, and 6 subjects reported receiving three or more previous episodes of
treatment for depression. The remaining 9 subjects reported an unspecified number of
previous episodes of treatment for depression.
Twenty-three subjects reported that they were taking one medication for
depression at the time of the initial screening, while 9 subjects reported the use of
two medications, and 1 subject reported taking three medications for depression.
Nine subjects reported using no medication for depression at the time of the initial
screening. When asked about the use of medication for depression prior to their
current medication (if any), 12 subjects reported that they had never been on an
antidepressant medication prior to the current medication, while 7 subjects reported
one prior medication. Nine subjects reported having been on two different
antidepressant medications before the current medication. Three subjects reported
having been on three or more medications for depression in the past. Eleven subjects
reported an unspecified number o f previous medications for depression.
The primary analyses were performed with data for all subjects who fulfilled
the requirements) o f their condition. The requirement for subjects in the treatment
condition was to complete a minimum of she sessions o f BAGT. Data from these
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subjects were used in both the between groups analysis (i.e., treatment condition vs.
wah-list condition) and the repeated measures analyses. The requirements for
subjects in the wait-list condition were to (a) complete a BDI-II at the end of the
wait-list period, and (b) complete a minimum of six sessions of BAGT. If wait-list
control subjects fulfilled both requirements, their data were included in both the
between groups analysis as well as the repeated measures analyses. If wait-list
subjects fulfilled only the first requirement, their data were included only in the
between groups analysis.
Pretreatment group differences were assessed through independent samples
t tests (see Figure 1 and Table 2). There were no significant pretreatment differences
between the treatment group and the wait-list group on BDI-II scores, t (32) = .124,
p = .90 or RHRSD scores, /(32) = 1.84, p - .08, suggesting that subjects in the
treatment condition and subjects in the wait-list condition came from the same
population.

□TX Group
BWL Group

BDMI

RHRSD

Figure I. Comparison of Pretreatment BDI-II and RHRSD Scores for Both Groups.
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Table 2
Pretreatment BDI-II and RHRSD Scores
TX Group (n = 12)

WL Group (n = 22)

Variable

M

SD

M

SD

BDI-II

36.8

(9.8)

37.2

(8.3)

/(32) = .12,/j = .90

RHRSD

19.4

(3-9)

22.7

(5-5)

tQ2) = l M , p = .08

r(dfs) andp

Note. TX = Treatment; WL = Wait-list; BDI-H = Beck Depression Inventory-Second Edition;
RHRSD = Revised Hamilton Rating Scale for Depression.
Primary Analyses
Table 3 presents the means, standard deviations, and results o f the between
groups analysis, while Figure 2 displays, graphically, the change in group means. The
between-groups treatment outcome analyses consisted of independent samples t-test
comparisons o f treatment condition outcomes to wait-list condition outcome with
BDI-D scores serving as the dependent variable. In the first analysis, the first point of
assessment was at screening for both conditions, while the second point of
assessment was immediately following treatment for subjects in the treatment
condition and immediately following the waiting period for subjects in the wait-list
condition. The independent samples /-test results, /(32) = 1.89, p = .07, revealed that
the difference in mean BDI-II scores between the treatment condition and the wait
list condition approached, but failed to achieve statistical significance at the .05 level.
In the second analysis, the points of assessment were the same except that for the
treatment group, the second point of assessment was at follow-up rather than at
posttreatment. The results yielded a statistically significant difference, /(32) = 3.85,
p —.00, between the treatment condition subjects and the wait-list condition subjects.
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Table 3
Mean Prewait-list and Postwait-list BDI-II Scores for Wait-list Subjects
and Mean Pretreatment, Posttreatment, and 3-Month Follow-up
BDI-n Scores for Treatment Subjects
WL Group

n

M

SD

n

M

SD

r(dfs) and/?

Pre

12

36.8

(9.8)

22

37.2

(8.3)

432) = .12,/? = .90

Post

12

29.0 (13.7)

22

36.9 (10.4)

432) = 1.89,/> = .07

Follow-up

12

21.3 (12.73)

22

36.9 (10.4)

/-S
U)

TX Group

II

oo

*X3

ii

u>
00
c /1

BDI-II

Note. BDI-II = Beck Depression Inventory-Second Edition; TX = Treatment; WL = Wait-list

□ Pre
■ Post
□ FoUow-up

TXQroup

WL Group

Figure 2. Prewait-list and Postwait-list Mean BDI-H Scores for the Wait-list Group
and Pretreatment, Posttreatment, and 3-Month Follow-up Mean BDI-H
Scores for the Treatment Group.
Consequently, while the results failed to uncover a statistically significant difference
between the wait-list group and the treatment group at posttreatment, a statistically
significant difference was obtained between the groups at follow-up. These results
are suggestive of a superiority for BAGT over a waiting period in the treatment o f
severe depression in a community sample.
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The second set of primary treatment outcome analyses consisted of paired
samples t tests comparing pretreatment scores to posttreatment scores and 3-month
follow-up scores and posttreatment scores to 3-month follow-up scores for all
subjects in the sample, with BDI-H and RHRSD scores serving as the dependent
variables. These analyses were performed for all subjects who completed treatment,
regardless o f their treatment condition. For treatment condition subjects, the
screening scores served as the pretreatment scores. For wait-list condition subjects,
the end of waiting period scores served as pretreatment scores. Figure 3 displays
mean BDI-II and RHRSD scores across time, while Table 4 presents the means, the
standard deviations, and the results of the repeated measures analyses.

40
35
30
25
20
15
10
5
0

-•-M ean BDI-II Scores
-•-M ean RHRSD Scores

Pretreatment Posttreatment

3-Month
Follow-up

Figure 3. Mean BDI-II and RHRSD Scores at Pretreatment, Posttreatment, and
3-Month FoUow-up for Total Sample.
The paired samples t tests for the total sample of subjects completing
treatment revealed a statisticaUy significant reduction in BDI-H scores from
pretreatment to posttreatment, /(25) = 3.46,/? < .01, and in RHRSD scores from
pretreatment to posttreatment, t(25) = 6.06,/? < .01. Paired samples t tests also
revealed a statisticaUy significant reduction in BDI-H scores from posttreatment to

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

43
3-month follow-up, t(l5) = 3.24, p < .01 and a reduction in RHRSD scores from
posttreatment to 3-month follow-up that approached statistical significance, /(25) =
2.00, p < .06.
Table 4
Pretreatment, Posttreatment, and 3-Month Follow-up Means
for BDI-II and RHRSD Scores for the Total Sample
n

M

(SD)

BDI-II
Pre
Post
3 months

34
26
26

37.3
30.2
24.1

(8.6)
(11.4)
(13-1)

r(25) = 3.46,/><.0l
r(25) = 3.24,/><.01*
r(25) = 4.56, p < .01

RHRSD
Pre
Post
3 months

34
26
26

21.6
12.5
10.4

(5.2)
(5.6)
(5.6)

f(25) = 6.06,p<.01
r(25) = 2.00,/? < .01®
f(25) = 6.I2,p<.0I

Depression Measure

t (dfs) and p

Note. BDI-II = Beck Depression Inventory-Second Edition; RHRSD = Revised Hamilton
gating Scale for Depression; TX = Treatment; WL= Wait-list = posttreatment to follow-up;
= pretreatment to follow-up.
Furthermore, statistically significant reductions from pretreatment to followup were observed for BDI-II scores, Z(25) = 4.56, p < .01 and RHRSD scores, /(25)
= 6.12, p < .01. When measured as an effect size, the difference in mean BDI-II
scores from pretreatment to follow-up was 1.50, representing a large effect (Cohen,
1988). These findings suggest that BAGT was associated with a significant reduction
in depression scale scores of a magnitude that was not likely to occur by chance
alone.
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Intent to Treat Analysis
A common practice in treatment outcome studies is to perform an-intent-to
treat analysis to control for subjects who dropped out of the study. This analysis is
performed by utilizing the dropout subjects’ screening scores on the dependent
measures as their posttreatment scores. This process is very conservative as it
assumes that subjects who dropped out of the study achieved no gains in their target
symptoms. The purpose of conducting an intent-to-treat analysis is to provide a view
of the effectiveness of the treatment for the entire sample, rather than merely for the
subjects who stayed in the study. This type of analysis is particularly important when
the subject dropout rate is high. For this study, the dropout rate was 38%.
Three intent-to-treat analyses were performed with this sample to assess
change on BDI-II scores, RHRSD scores, and in diagnosis from pretreatment to
posttreatment. Paired samples t tests revealed statistically significant reductions in
both BDI-n scores, /(41) = 3.20, p < .01, and RHRSD scores, /(31) = 5.3 8, p < .01,
suggesting that BAGT was still associated with a significant reduction in depression
scale scores when controlling for dropouts. A paired samples t test also revealed a
significant reduction in Major Depressive Disorder diagnoses, /(4l) = 5.55, p < .01,
from screening to posttreatment, suggesting that B AGT was associated with a
significant reduction in the number of Major Depressive Disorder diagnoses in the
sample when dropouts were factored into the analysis.
Allegiance Analysis
BAGT was administered at four different agencies by four different co
therapist teams. As such, analyses o f outcome by agency were performed to examine
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whether differential outcomes occurred as a function of therapist team. Two one-way
analyses o f variance, with three levels of the agency as the independent variable (the
small sample size at the fourth agency did not permit inclusion in this analysis) and
posttest BDI-II and RHRSD scores as the dependent variables, yielded no significant
differences between agency groups on either the BDI-II, F(2, 21) = .306, p = .740, or
the RHRSD, F (2,21) = .122,/? = .886. Therefore, there was no reason to suspect
that treatment outcome differed significantly from one agency to another.
Post-hoc Analyses
A set of post-hoc analyses that provided interesting findings was examination
of outcome measures as a function of medication status of the subjects. Mean BDI-II
and RHRSD scores at all assessment times were examined by separating the sample
into medication subjects and no medication subjects (74% of the treatment
completers were receiving independently prescribed pharmacological treatment for
depression while receiving BAGT). The reader is referred to Figures 4 and 5 and
Table 5 for these data. Independent samples t tests with medication status as the
independent variable and BDI-H and RHRSD scores as the dependent variables
revealed no statistically significant pretreatment differences on BDI-H scores, /(32) =
.41,/? = .69, or RHRSD scores /(32) = .60, p = .56. At posttreatment, a statistically
significant difference on RHRSD scores was observed, /(24) = 2.53, p < .05, though
the difference on BDI-H scores failed to achieve statistical significance, /(24) =1.15,
p = .26. At 3-month follow-up, differences on RHRSD and BDI-II scores
approached statistical significance, /(24) = 1.91,/? = .07, and /(24) = 1.75,/? = .09,
respectively. Thus, when utilizing the RHRSD as the outcome measure, subjects who
received BAGT without antidepressant medication achieved significantly lower
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scores at the end of treatment compared to subjects who received BAGT along with
antidepressant medication.
25
20

15

-No MM
-MM

Q
CO 10
ne
x
ac

5

0
3-Month Follow-up

Figure 4. Mean RHRSD Scores as a Function of Medication Status.
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Figure 5. Mean BDI-II Scores as a Function of Medication Status.
These differential outcomes as a result o f medication status prompted
repeated measures analyses of BAGT only subjects and BAGT plus medication
subjects to provide a perspective of how each groups o f subjects responded to
BAGT. When BAGT was added to an existing medication regimen, repeated
measures /-tests revealed a near statistically significant reduction in BDI-II scores
from pretreatment to posttreatment, /(17) = 1.84, p = .08, a statistically significant
reduction from posttreatment to 3-month follow-up, /(17) = 2.16, p < .05, and a
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Table 5
Mean BDI-II and RHRSD Scores as a Function of Medication Status
Medication

No Medication
n

M

n

(SD)

M

(SD)

BDI-II
Pre
Post
3-Month

9
8
8

38.11 (8.70)
26.38 (12.76)
17.63 (13.19)

25 36.72 (8.85)
18 31.89 (10.67)
18 26.94 (12.31)

RHRSD
Pre
Post
3-Month

9
8
8

20.67
8.75
6.63

25 21.88
18 14.22
18 12.11

(4.47)
(4.10)
(2.43)

(5.48)
(5.45)
G-58)

t (dfs) andp
/(32) = .406,/> = .69
r(24)=I.15,/> = 26
r(24)=l.75,/? = .09
t(32)=.60,p = .56
f(24)=2.53,/7 = .02
f(24)=l.91,p = .07

Note. BDI-II = Beck Depression Inventory-Second Edition; RHRSD = Revised Hamilton
Rating Scale for Depression
significant reduction from pretreatment to 3-month follow-up, /(17) = 3.11, p < .01.
This trend continued and produced a statistically significant reduction from
posttreatment to 3-month follow-up, /(17), = 2.16, p < .05. These analyses suggest
that the addition of BAGT to antidepressant medication resulted in significant
reductions in depressive symptomatology.
Evaluating the results of BAGT when administered to subjects without
concurrent medication use, paired samples t tests revealed statistically significant
reductions in mean BDI-II scores from pretreatment (M = 38.9) to posttreatment
(M= 26.4), t(T) = 3.0, p < .05, from posttreatment to 3-month follow-up (M = 17.6),
t(l) - 2.6, p < .05, and from pretreatment to 3-month follow-up, /(7) = 3.8, p < .01.
These results suggest that BAGT was associated with significant reductions in
depression when administered to subjects who were not receiving pharmacotherapy
for depression.
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Diagnostic Outcome
As an additional measure of clinically significant change, DSM-IV diagnoses
at screening were compared with DSM-IV diagnoses at posttreatment and 3-month
foliow-up. Figure 6 and Table 6 present the frequency of major depression diagnoses
at these three times for all subjects who completed treatment. At screening, 26
subjects (100%) met DSM-IV criteria for Major Depressive Disorder. At
posttreatment, 8 subjects (30.8%) met DSM-IV criteria for Major Depressive
Disorder, while at 3-month follow-up, 7 subjects (26.9%) met DSM-IV criteria for
Major Depressive Disorder. These results suggest that approximately 2 out of every
3 subjects who received BAGT no longer met diagnostic criteria for Major
Depressive Disorder immediately following treatment. Furthermore, approximately 3
out o f every 4 subjects were free of a Major Depressive Disorder 3 months after
treatment.

MP f cantaga of Sampte Matting DSMIVCriteria for Major Daprauivo
Diaowfar(M»2B)____________

Figure 6. Percentage of Treatment Completers Meeting DSM-IV Criteria for Major
Depressive Disorder at Screening, Posttreatment, and 3-Month Follow-up
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Table 6
Number of Treatment Completers Meeting DSM-IV Criteria for Major
Depressive Disorder at Pretreatment, Posttreatment, and Follow-up

Major Depressive
Disorder

Pretreatment
n (% of sample)

Posttreatment
n (% of sample)

3-Month FoUow-up
n (% of sample)

26 (100%)

8 (30.8%)

7 (26.9%)

Client Satisfaction With Treatment
To measure subject satisfaction with BAGT, a 5-point Likert scale was
utilized at posttreatment. This scale asked subjects to rate BAGT on a continuum
from “much worse” to “much better.” These results are presented in Table 7. At
posttreatment, 25% of the sample rated it “much better” than individual therapy,
while 12.5% rated it “better” than individual therapy. Forty-one and seven tenths
percent (41.7%) rated it “about the same” as individual therapy. Sixteen and seven
tenths percent (16.7%) rated it “much worse” than individual therapy. Compared to
other therapy groups, 20.8% rated BAGT at “much better,” while another 20.8%
rated it as “better.” Twelve and five tenths percent (12.5%) of the sample rated
BAGT “about the same” as other therapy groups, while 45.8% could not make a
comparison due to lack of previous experience with group therapy.
When asked to rate the Behavioral Activation approach compared to other
therapy approaches with which subjects had experience, 47.8% rated it “much
better,” while 34.8% rated it “better.” Four and three tenths percent (4.3%) rated the
Behavioral Activation approach as “worse” than other approaches. Thirteen percent
(13%) did not have a basis for comparison. In terms o f the subject rated effectiveness
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Table 7
Subject Ratings o f BAGT at Posttreatment and 3-Month Follow-up
Question

Much
Worse/
Worse
n (%)

Worse

Same

Better

n (%)

«(%)

n (%)

Much
Better/
Best
n (%)

P o st t r e a t m e n t

BAGT vs ind.
therapy
BAGT vs other
group therapies
BA vs other
approaches
BAGT vs other
therapies
(effectiveness)
BAGT vs meds
(process)
BAGT vs meds
(effectiveness)
Rate depression
after BAGT
Rate BAGT
overall

4 (16.7%)

0 (0.0%)

10 (41.7%)

3 (12.5%)

6 (25.0%)

0

(0.0%)

0 (0.0%)

3 (12.5%)

5 (20.8%)

5 (20.8%)

0

(0.0%)

I (4.3%)

0

(0.0%)

8 (34.8%)

11 (47.8%)

0

(0.0%)

0 (0.0%)

7 (31.8%)

5 (22.7%)

8 (36.4%)

0

(0.0%)

0 (0.0%)

4(22.2%)

8 (44.4%)

2 (11.1%)

0

(0.0%)

1 (5.3%)

5 (26.3%)

7 (36.8%)

3 (15.8%)

0

(0.0%)

0 (0.0%)

7(28.0%)

13 (52.0%)

4 (16.0%)

0

(0.0%)

0 (0.0%)

5 (20.0%)

5 (20.0%)

14 (56.0%)

Strong No
«(%)
Recommend
BAGT to a
friend?
Go through
BAGT again?
3-Month
Fo l l o w -u p

Depression
compared to 6
months ago

bio
n (%)

Mavbe
n (%)

Yes
n (%)

Strong Yes
«(%)

0 (0.0)

I (4.0%)

3 (12.0%)

2 (8.0%)

17 (68.0%)

1 (4.0%)

1 (4.0%)

2 (8.0%)

4(16.0%)

16 (64.0%)

Worse
n (%)

Same
n (%)

0 (0.0%)

6(24.0%)

Yes
BAGT helpful in 18 (72.0%)
managing
depression?
BAGT provide
20 (80.0%)
long-term
benefits?

No
6(24.0%)

Better
«(%)
18 (72.0%)

4(16.0%)
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of BAGT compared to other therapies, 36.4% of the sample rated it as “much
better,” with 22.7% rating it as “better” and 31.8% rating is as “about the same” in
its ability to treat depression. Nine and one tenth percent (9.1%) of the sample could
not make a comparison.
When asked to rate how the process o f BAGT compared to the process of
taking medication, 11.1% rated it “much better,” with 44.4% rating BAGT as
“better,” and 22.2% rating it as “about the same.” In terms of the subject-rated
effectiveness of BAGT compared to medication, 15.8% rated BAGT as “much
better,” while 36.8% rated BAGT as “better,” and 26.3% rated BAGT as “about the
same.” Five and three tenths percent (5.3%) rated BAGT as “worse” than
medication.
Subjects were asked to rate their depression immediately following treatment.
Sixteen percent (16.0%) rated their depression as “much better” than before receiving
BAGT, while 52.0% of the sample rated their depression as “better” compared to
when they started BAGT. Twenty-eight percent (28.0%) of the sample rated their
depression as the “same” as when they started BAGT. When asked to rate BAGT
overall, 56.0% rated it as the “best” therapy they ever had. Twenty percent (20.0%)
rated BAGT as “better” than average, while another 20.0% rated it as the “same” as
other therapies. When asked whether they would recommend BAGT to a friend
suffering from depression, 68.0% responded that they would “strongly recommend”
it to a friend. Eight percent (8.0%) responded that they would “probably
recommend” it to a friend, while 12.0% responded they would “maybe recommend”
it to a friend. Four percent (4.0%) reported that they would “probably not”
recommend it to a friend. Finally, when asked if they would go through BAGT again,
64.0% responded that they “definitely would,” 16.0% responded that they “probably
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would,” 8.0% responded that they “maybe would,” 4.0% responded that they
“probably would not,” and 4.0% responded that they “definitely would not” go
through BAGT again.
Client Report of Depression at Follow-up
At 3-month foUow-up, subjects were asked to rate their depression compared
to 6 months prior with an open-ended question. This response was then categorized
into same-better-worse categories. Examples o f responses coded as “better”
included: “better,” “not as bad,” “less of a problem,” and “it causes less problems in
my life ” Examples of responses coded as the “same” include: “about the same,” “no
better,” “no worse,” and “still a problem.” Seventy-two percent (72.0%) o f the
sample rated their depression as “better,” while 24.0% rated their depression as the
“same” as 6 months ago. One subject did not respond to this item. When asked if
BAGT provided long-term benefits for managing depression, 80.0% stated “yes,”
while 16.0% stated “no.” One subject did not respond to this item.
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CHAPTER V
DISCUSSION
The purpose of this study was to examine the effectiveness o f Behavioral
Activation Group Therapy as a treatment for Major Depressive Disorder in a sample
of “real world” subjects. Research has demonstrated the efficacy of Behavioral
Activation treatment for clinical depression as an individual therapy in the laboratory
(Jacobson et al., 1996). The primary question addressed by this study was whether or
not BA could be an effective treatment for clinical depression when delivered by
CMH clinicians to CMH clients in a group format. Due to the parsimony of BA, it
was hypothesized that the aforementioned goal could be achieved, thereby supporting
BAGT as a clinically effective and cost-effective treatment for depression.
Main Outcomes
While the results of this study failed to demonstrate a clear-cut advantage for
10 weeks of BAGT over a WLC condition in the treatment o f severe clinical
depression in a CMH population, they did suggest that over the foUow-up period,
BAGT was associated with a further reduction in depressive symptomatology that
was superior to any reduction associated with the wait-list. As such, one could
conclude that placing a depressed patient on a waiting list for BAGT was as effective
in managing depression in the short run as providing BAGT. However, a closer
examination of the results may support a less decisive interpretation.
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The absence of a statistically significant difference in outcome scores between
treatment condition subjects at posttreatment and wait-list condition subjects may
best be explained from a statistical perspective, rather than from a clinical
perspective. In defense of BAGT, it is likely that the small sample size of the
treatment group yielded insufficient power to detect a real difference between the
treatment group and the wait-list group when such a difference may have existed. To
assess the relative contribution of the small sample size, a hypothetical analysis was
performed by adding subjects to the treatment group utilizing the BDI-H
posttreatment mean score for the treatment group as the posttreatment scores for the
hypothetical subjects. This analysis revealed that, while maintaining the original
between groups difference, adding only 2 subjects to the treatment group resulted in
a statistically significant between-groups difference *(34) = 2.04, p < .05. As such, if
the observed between-groups difference at posttreatment had occurred with only 2
more subjects in the treatment group, a significant difference between the treatment
group and the wait-list group would have occurred. Thus, it is possible that a
significant difference between groups did exist; yet, this difference went undetected
by statistical methods due to the small sample size.
A more useful way to approach the between groups data may be to look at
the actual change in group means. The mean BDI-II score for the wait-list group
changed from 37.2 at pre-waiting period to 36.9 at post-waiting period. Subjects in
the wait-list condition, as a whole, experienced no meaningful reduction in their BDIII scores over the course of the waiting period. This absence o f change suggests that
depression did not improve as a result o f being on the wait-list. Examining the data in
this fashion assists in uncovering the primary reason for utilizing a wait-list control
condition—to assess change in target symptoms associated with each condition. The
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study demonstrated that for this sample of depressed individuals, neither the passage
of time, nor the effect of repeated assessment, nor the influence of existing
pharmacological agents was sufficient to produce a reduction in depression scale
scores.
Conversely, inspecting the data for the 12 subjects in the treatment group
revealed a near significant reduction in mean BDI-II scores from pretreatment (36.8 )
to posttreatment (29.0), /(l 1) = 2.10, p = .06, and a significant reduction in mean
BDI-II scores from pretreatment (36.8) to 3-month follow-up (21.3), /(12) = 3.66,
p < .01. Interpreting these mean scores within the parameters established for the
BDI-H suggests that treatment group subjects experienced a shift from severe to
moderate depression after 10 weeks o f treatment, followed by continued
improvement to low-moderate depressive symptomatology at follow-up.
Consequently, although the difference on BDI-H scores between the treatment group
at posttreatment and the wait-list group may not have been large enough to achieve
statistical significance with this sample, the results demonstrated that subjects on the
waiting list did not experience any improvement in their depression, whereas subjects
who received BAGT experienced an improvement in their depression that may have
been clinically significant at 10 weeks and that was statistically and, presumably,
clinically significant at follow-up.
The second main finding, that BAGT was associated with a significant
reduction in BDI-H scores, RHRSD scores, and Major Depressive Disorder
diagnoses after 10 weeks of treatment, is encouraging given this difficult-to-treat
sample. This finding implies that, overall, levels of depression decreased significantly
for subjects who received six or more sessions o f BAGT. Furthermore, scores on all
outcome measures continued to decrease at 3-month follow-up, suggesting that the
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change process that occurred during treatment continued after therapy had ended.
This latter finding has important implications for understanding the psychotherapeutic
process of BAGT. These results suggest that in addition to facilitating antidepressant
change during the course of therapy, 10 sessions of BAGT equipped subjects with
knowledge and skills that enabled them to continue the antidepressant change process
after formal treatment had concluded. This supports the effectiveness of BAGT as an
adjunct, if not a stand-alone treatment for severe depression in a CMH population.
An obvious criticism of this interpretation lies in the observation that the
posttreatment BDI-H sample mean of 30.2 represents a severe level of depression.
Beck, Steer, and Brown (1996) identified a BDI-H score of 30 as the cut-off score
between moderate and severe depression. One could therefore argue that BAGT was
associated only with a change from severe to moderate/severe depression, failing to
return subjects to a state of health. This raises the question, “What is an acceptable or
a successful outcome?” One way to address this question is to consider the severity
of the depression and the history o f treatment success/failure in the sample. Seventynine percent (79%) of the sample entered the study with a diagnosis of recurrent
depression. This suggests that for a majority of these subjects, depression was a
chronic condition. One hundred percent (100%) of the sample was involved in formal
treatment for depression at the time o f screening, with 83% of the subjects receiving
medication for depression, considered by some the treatment of choice for severe
depression (Elkin et al., 1989). Despite these pharmacological and psychotherapeutic
treatments, 100% o f the subjects met DSM-IV criteria for Major Depressive
Disorder, in addition to scoring at least in the range o f moderate depression on two
outcome measures. In actuality, the sample as a whole scored in the range o f severe
depression on the BDI-H and the RHRSD at screening. This information suggests
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that the depression experienced by the sample was severe, chronic, and refractory to
pharmacological and psychotherapeutic efforts. As such, any improvement in
depressive symptomatology would seem to be significant for this sample, and,
consequently, an appropriate expectation may have been only a reduction in
symptoms, rather than a return to health.
Another standard by which to assess treatment outcome is to compare it to a
similar treatment for the same condition. Jacobson et al. (1996) obtained impressive
results with their use of BA to treat depression. The results of the present study fell
short of the degree of depression scale score reduction obtained in that study, with a
posttreatment mean BDI-H score of 30.2 compared to a posttreatment BDI-H mean
of 9.1. In that study, Jacobson et al. (1996) moved subjects from a moderate/severe
level of depression to no clinical depression (as measured by the BDI) with 16 weeks
of BA. In the present study, subjects moved from severe depression to moderate/
severe depression with 10 weeks of BAGT. Aside from the possibility that BAGT
may not have been as effective a treatment for depression as BA, the explanation^)
for these different outcomes may lay in understanding the differences between the
two samples.
Several significant differences existed between the present sample and the
Jacobson et al. (1996) sample. Foremost, the present sample consisted of individuals
with more severe depression, as evidenced by a pretreatment mean BDI-H score that
was 8 points higher (M= 37 vs. M - 29) than the mean BDI-H score for the
Jacobson et al. (1996) sample. This difference represented a 28% higher BDI-H mean
score for the present sample compared to the other sample. Difference in level o f
initial severity o f depression has been associated with differential outcomes, with
higher levels of severity resulting in poorer response to cognitive-behavioral

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

58
treatment (Elkin et al., 1989). Consequently, it is possible that the comparatively
higher posttreatment BDI-II scores obtained in the present sample were a function of
the initial severity of the depression, rather than a function of ineffective treatment.
A second factor that differentiated the present sample from the Jacobson et al.
(1996) sample was that 84% o f the present sample were being treated
pharmacologically for depression, whereas subjects in the other study were without
medication for depression. The methodology of the present study required subjects
on medication to be stabilized at a maintenance dose of the medication for a minimum
of 6 weeks prior to screening in order to be considered for participation. Therefore,
84% of the sample scored in the range o f moderate to severe depression on the BDIII and the RHRSD, despite pharmacological treatment for depression. As such,
before initiating BAGT with these subjects we had knowledge regarding baseline
response to medication. When BAGT was added to the medication regimen, these
patients experienced a drop in BDI-II scores from pretreatment (36.6) to
posttreatment (31.9). This trend continued at 3-month follow-up (26.9), representing
a 26% reduction in depression scale scores from the pretreatment mean and a
moderate level of depression. These results suggest that BAGT was associated with a
significant reduction in depression scale scores, despite utilizing a sample of subjects
whose depression was likely more resistant to treatment than that of the Jacobson et
al. (1996) sample.
To control for medication use in this study, we looked solely at the data for
those subjects who received BAGT without concurrent pharmacological treatment
and compared those data to the data from Jacobson et al. (1996). These data are
presented in Figures 7 and 8 and Table 8. This analysis permitted comparison of
pretreatment, posttreatment, and follow-up BDI-II and RHRSD scores between two
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similar samples of subjects. With the medication factor controlled for, a decreasing
trend in outcome scores similar in magnitude to that of Jacobson et al. (1996) was
observed for the present sample. Posttreatment and follow-up means for the present
sample remained higher than those of the comparison sample, but were proportional
to the pretreatment differences that existed between the samples. This suggested that
the magnitude of change experienced by no medication subjects in the present study
approximated the magnitude of change experienced by subjects in the Jacobson et al.
(1996) study. This finding supports BAGT’s effectiveness as a treatment for clinical
depression.
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Figure 7. Mean BDI-II Scores for This Sample and for the Jacobson et al. (1996)
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Figure 8. Mean RHRSD Scores for This Sample and for the Jacobson et al. (1996)
Sample.
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Table 8
Pretreatment, Posttreatment, and Follow-up BDI-H and RHRSD Scores
for Subjects in This Sample Compared to Subjects
in the Jacobson et al. (1996) Sample
Porter and Spates (2000)

Jacobson et al. (1996)

n

M

(SD)

n

M

(SD)

Pre
Post
Follow-up

8
8
8

38.88
26.38
17.63

(8.97)
(12.76)
(13.19)

56
56
50

29.3
9.1
8.5

(6.6)
(7.9)
(7.6)

RHRSD
Pre
Post
Follow-up

8
8
8

21.50
8.75
6.63

(3.96)
(4.10)
(6.86)

56
53
50

17.4
6.4
6.6

(3.9)
(4.6)
(4.8)

bdi -h

Note. BDI-H = Beck Depression Inventory-Second Edition; RHRSD = Revised Hamilton
Rating Scale for Depression
Secondary Outcomes
A post-hoc analysis that produced intriguing results was an examination of
outcome measures as a function of medication status. Statistical tests revealed a
significant difference in RHRSD scores at posttreatment between subjects receiving
medication and subjects not receiving medication. This trend continued at 3-month
follow-up at a rate that approached significance (p —.07). These results favored
subjects who did not receive medication, with their posttreatment and follow-up
scores placing them in the range of mild depression, while subjects who received
medication still scored in the range of moderate depression immediately after
treatment and at follow-up. Barlow (1997) observed a similar pattern in a Panic
Disorder treatment outcome study. The results o f the study suggested that subjects
who received only the psychotherapeutic intervention fared better on outcome
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measures than subjects who received both the psychotherapeutic intervention and the
pharmacological intervention.
Several interpretations could explain why subjects who received BAGT alone
apparently benefited more than subjects who received BAGT along with
antidepressant medication. First, it is possible that the subjects who were not on
medication were the subjects with single episode depression, whereas the subjects
who were on medication were the subjects with recurrent depression or double
depression. If such a difference existed between the two groups, it could have been
this factor, and not the medication factor, that was responsible for the differential
outcomes. Consequently, initial diagnoses were compared for both groups of
subjects. This analysis revealed that in the no-medication group, 67% of the subjects
received an initial diagnosis o f recurrent depression, while 33% received a diagnosis
o f single episode depression. These percentages were similar to those of the
medication group, with 78% of the mediation group receiving an initial diagnosis of
recurrent or double depression and 22% receiving a diagnosis o f single episode
depression. This analysis suggests that initial diagnosis was not a factor in
determining the differential outcomes between the medication and the no-mediation
groups.
Second, it is possible that the subjects on medication were the subjects with
refractory depression. Their exposure to pharmacological treatment had already
demonstrated the resilience of their depression, and consequently, antidepressant
change may have been less likely to occur for these individuals. In other words, these
individuals had treatment histories that made significant improvement in depression
unlikely. As such, their depression scale scores decreasing as they did supports the
relative effectiveness of BAGT.
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A third interpretation, and one that stems from a more psychological
perspective, is that subjects who were not receiving medication for depression put
more “stock” in BAGT, as it was their primary treatment. As a result, their
expectations for BAGT may have been greater than the expectations of the
medication subjects, which in turn may have affected their behavior in therapy. For
example, believing that they did not need medication to overcome depression, these
subjects may have expected the work that they put into BAGT to relieve their
depression. Viewing BAGT as their means to recovery, they may have invested more
energy into therapy than the medication subjects and, as a result, benefited more from
BAGT. Conversely, subjects who received medication may have believed that BAGT
was only for talking about problems or meeting new people. As such, they may not
have seen the value in BAGT, and their investment in therapy, and the subsequent
return, may have been minimal.
A third interpretation of the aforementioned finding is that subjects receiving
medication may have viewed depression primarily as a biological illness (i.e.,
chemical imbalance), and, consequently, had little belief in BAGT as a treatment for
depression. For example, medication subjects may have believed that depression, like
an ear infection, required medication for successful treatment. They may have
believed that attending BAGT could not hurt them, but that any improvement in their
depression would result from their medication. And because BAGT, like other
cognitive-behavioral treatments, required active involvement on part of the subject,
the results o f BAGT for these subjects may have been less than those for other
subjects. In sum, subjects who did not receive medication along with BAGT seemed
to benefit more from BAGT than subjects who received BAGT and medication. This
differential outcome may have reflected differences in expectations for BAGT,
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differences in the investment subjects made into B AGT, or differences in
understanding depression and its treatments.
Social Validity
Subject satisfaction data suggested that overall, BAGT was a well-tolerated
and well-received treatment for depression. The majority of subjects who completed
BAGT rated it as superior to other group therapies with which they had experience.
Also, the majority of subjects rated Behavioral Activation as superior to other
approaches to therapy. Most subjects rated BAGT as equal to or more effective than
medication for depression. Furthermore, more than one-half of the subjects rated
their depression as improved after receiving BAGT. Overall, subject ratings of BAGT
and its effectiveness suggested that it was a valuable tool for treating depression; one
that most subjects would utilize again if given the opportunity.
The social validity data obtained from this study endorsed BAGT as an
acceptable form of treatment, which is promising for several reasons. First, group
therapy can be seen by patients as “second rate” treatment. Consequently, to have a
majority o f the treatment completers rate BAGT favorably compared to other
treatments (e.g., individual therapy, medication) suggests that group therapy can be
desirable if organized properly. This bodes well for today’s health care providers, as
group therapy has been shown to hold advantages over individual therapy in terms of
conservation of clinician and third party resources (Piper & Joyce, 1986). The finding
that the majority o f subjects rated the BA approach as superior to other therapy
approaches was encouraging, given the newness of BA. This suggests that in addition
to being clinically effective (Jacobson et al., 1996), the Behavioral Activation
approach fits well into subjects’ expectations for therapy and that it provides
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experiences that subjects consider meaningful. This type of appraisal is likely to
facilitate continued use of and research into BA approaches for treating depression.
Limitations o f This Study
Several limitations of this study were inherent in conducting it as an
effectiveness study. For example, experimental control was sacrificed in order to
conduct the research in a “real world” setting. One sacrifice was our inability to
collect treatment adherence data on the BAGT therapists. We were unable to collect
these data due to the physical structures of the participating CMH agencies; the
group therapy rooms did not have observation capabilities. Without these data, we
were less certain that the treatment delivered was that treatment which was
prescribed by the study. The inclusion o f in-session BAGT subject manuals
encouraged a focus on Behavioral Activation principles; however, we were resigned
to rely upon clinician reports of their own therapy and upon our own beliefs about
therapist training and performance as indicators of treatment adherence.
A second limitation of the study was our inability to randomly assign subjects
to the treatment or the wait-list condition. Because the CMH agencies preferred to
recruit subjects from existing clients rather than to advertise outside the agencies, we
were limited in our access to potential subjects. Mass subject accumulation was
therefore difficult and was replaced by a trickle-in o f subjects that occurred over a 4to 8-week period. This quasi-experimental design was inferior to a true experiment in
which assignment to treatment condition would have been manipulated by the
experimenter. As a result, we encountered problems such as unequal sized groups
(i.e., treatment group, wak-Iist group) which made interpretation o f the data difficult
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Finally, as previously discussed, was the limitation associated with the small
sample size; this was problematic with respect to the between-group analysis. The
small size of the treatment group yielded low power, which in turn made it difficult to
detect real differences between conditions if they existed. This, coupled with the
severity o f depression of the sample, made it difficult to show a statistically
significant difference between the treatment group and the wait-list group. As
previously suggested, the between-groups difference that occurred may have been
real as well as the largest difference that could have been achieved with this
population; however, the small sample size prevented the difference from achieving
statistical significance. If this was the case, then the weakness of the study may lay
not with the treatment but with the size of the sample.
Conclusions and Future Directions
The results of this study support BAGT as a valuable approach for treating
clinical depression. Although BAGT was not associated with the same degree of
antidepressant change that has been achieved in the cognitive-behavioral literature,
the severity of this population may explain this outcome. Because this was the first
study to employ Behavioral Activation Group Therapy, one purpose was to provide
an indication of whether or not further pursuit of BAGT is warranted. These results
support continued examination of the benefits of BAGT as an adjunct as well as a
stand-alone treatment for clinical depression.
One direction for future evaluation of BAGT would be to utilize this
treatment with a population o f persons with less severe depression. Such an effort
would provide a valuable view of BAGT’s utility with a population that may respond
better to treatment. A second direction would be to evaluate the effects o f a longer
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course of BAGT, as many subjects provided feedback suggesting that 10 weeks o f
treatment was inadequate. In other words, with the population utilized in the present
study, depression treatment, such as BAGT, may need to be conceptualized as part of
a sustained treatment program that is available to the individual as needed to maintain
therapeutic gains. For this population, the notion o f a pre-determined length of
treatment may fail to appreciate the complexity and the resiliency of the illness.
Finally, future evaluation of BAGT would benefit from employing a larger sample.
Given that depression varies in severity and in course, it will be important to collect a
large enough sample that the investigators) have the statistical power to detect even
moderate changes in depression scale scores; these changes may be the best
outcomes attainable with difficult-to-treat populations.
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To be read to persons interested in the study:
“The Department of Psycho logy at Western Michigan University and (name
o f C M H

a g e n c v l

are conducting a study to assess the effectiveness of a new group

therapy treatment for depression. Past research has shown that this type o f therapy
has been very effective with adults experiencing problems with depression. The
therapy is a solution-focused approach to treating depression and clients are assisted
in breaking the cycle of depression that has developed through making strategic
changes in behavior. The group of 6-8 clients will meet once a week for 10
consecutive weeks. Therapy sessions will last for 95 minutes.
Adults experiencing problems with depression are encouraged to schedule an
appointment for an intake interviewed to be assessed for acceptance into the study.
Participation in an interview in no way obligates you to participate in the study, but it
serves to give both you and the researchers a better understanding of how
appropriate the therapy would be for you. If accepted into the study, you would be
expected to complete the 10-week course of treatment which would require
approximately 90 minutes of your time per week. In addition, you would be expected
to perform certain tasks between therapy sessions that are aimed at relieving your
depression.
Are you interested in participating?”
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Western Michigan University
Department of Psychology
Principal Investigator C. Richard Spates, Ph.D.
Student Investigator Jeffrey F. Porter, M.A.
I have been invited to participate in a research project entitled “Southwestern
Michigan Treatment of Depression Collaborative Study: Behavioral Activation
Group Therapy: An Initial Investigation.” This research is intended to study the
effects o f a particular group treatment for depression with adults in a community
setting. This project is Jeffrey F. Porter’s dissertation project.
My consent to participate in this project indicates that during my intake interview, I
will be asked to provide some personal information on a brief questionnaire and to
complete a form asking questions about the symptoms o f depression that I have
experienced during the past two weeks. Also during my intake interview I will be
interviewed to further assess my symptoms of depression and general mental health.
If my condition is not appropriate for participation in the study, I will be referred
back to the agency for mental health services. If I am invited to participate in the
treatment, I will be assigned to a therapy group of 6-10 persons led by two therapists
at this agency. If asked, I agree to wait for up to four weeks for treatment to begin
and will not begin any other treatment for my depression during this period. The
purpose of this group therapy is to assist group members in overcoming their
depression. I will be asked to attend 10 weekly group therapy sessions o f
approximately 95 minutes each. I will be asked to spend the first 5 minutes o f each
therapy session completing a depression questionnaire and to complete certain tasks
between therapy session that are aimed at relieving my depression. At the end of the
10 week treatment, I will again be asked to complete the depression questionnaire
and be interviewed again to assess my symptoms o f depression and general mental
health. Finally, three months after treatment has concluded, I will again be asked to
complete the depression questionnaire and will again be interviewed to assess my
depressive symptoms and my general mental health. I am aware that other types of
treatment for depression, such as individual psychotherapy or medication treatment,
are typically effective and I may have access to these services if I choose not to
participate in this study.
As in all research, there may be unforeseen risks to the participant. If an accidental
injury occurs, appropriate emergency measures will be taken; however, no
compensation or treatment wfil be made available to me except as otherwise specified
in this consent form. One potential risk of my participation in this project is that I
may experience unpleasant emotions, including anger, frustration, depression, and
disappointment, as I recall my problems and experiences and actively work to change
certain behaviors in order to reduce my depression. I am informed that this agency is
prepared to make a referral should emergency care become necessary. I will be
responsible for the cost o f emergency care should such care become necessary.
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I may benefit from participating in this study in several ways. Primarily, I may
experience a significant reduction in my depression as a result of receiving thus
treatment. Also, by becoming a member of a small treatment group, I may benefit
socially from interactions with others having similar experiences to mine. Finally, I
may learn more about psychological treatment and group therapy which may assist
me in making future decisions regarding mental health care. Additionally, I and others
seeking treatment for depression in the future may benefit from the knowledge that is
gained by this research.
All research information collected from me is confidential. This means that my name
will not appear on any research questionnaires I complete or on any other research
forms that contain personal information that I have provided. These forms will be
coded and Jeffrey Porter will keep a separate master list with the names of the
participants and the corresponding code numbers. The master list will be the only link
between the data on the recording forms and my identity. Once all data are collected
and analyzed, the master list will be destroyed. These forms will be kept in a research
folder in a locked file cabinet in this clinic during my participation in the study. I am
informed that the policy o f this clinic requires that progress notes and other
information about me be recorded and placed in a treatment folder. This is necessary
because by participating in this study, I also am a client of this clinic. However, the
information in my treatment folder belongs to the clinic and may not be used as data
for this study. I am informed that forms used in this study may be duplicated and
placed in my treatment folder where they will be retained until they are destroyed
along with the rest of the papers in my treatment folder according to the policies o f
the clinic. At the end of my participation in the study, my research folder will be
moved to a locked cabinet in the Department of Psychology where it will be stored
for a minimum of three years after the completion of this study. It will then be
destroyed.
I may refuse to participate or quit at any time during the study without prejudice or
penalty. If I have any questions or concerns about this study, I may contact either Dr.
Richard Spates at (616) 387-4329 or Jeffrey Porter at (616) 353-8650. If I have
questions about my rights as a research participant or about any other aspects of my
participation, I also may contact the Chair of Human Subjects Institutional Review
Board at (616) 387-8293 or the Vice President for Research at (616) 387-8298 with
any concerns that I have.
This consent document has been approved for use for one year by the Human
Subjects Institutional Review Board as indicated by the stamped date and signature
of the board chair in the upper right comer of each page. Subjects should not sign
this document if all upper right comers do not have a stamped date and signature.
My signature below indicates that I have read and/or had explained to me the purpose
and requirements o f the study and that I agree to participate.
Signature
Consent obtained by:____________________
initials o f researcher

Date
____________
Date
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Demographics Questionnaire
Research Code Subject Number:___________________
Date of B irth:______ /_____ I
month day year

Age:____________
Gender: (Circle one) Male Female

Ethnicity: (Mark best choice)
African American_____
American Indian_____
Asian American_____
Alaskan American_____
Caucasian (white)_____
Hispanic_____
International/non US Resident_____
Other (please specify):____________________
Relationship Status: (Mark best choice)
Single, never married_____
Living with significant other_____
Separated_____
Divorced_____
Married_____
Years of Education: (mark best choice)
Less than 12 years_____
12 years or GED_____
More than 12 and less than 16 years_____
16 years_____
16+ years_____
Household Income: (Mark best choice)
Under $ 10,000 per year_____
$10,000-520,000 per year_____
$20,000 -$30,000 per year_____
Over $30,000 per year_____
(Over)
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•

Are you currently receiving treatment for depression?
Yes
No _____
If yes, what type of treatment? (Mark all that apply)
• Medication Treatment_____
• Hospital (Inpatient or Partial Hospitalization) Care_____
• Pastoral Care_____
• Individual Therapy_____
• Group Therapy_____
• Support Group____

•

Have you been in treatment for depression in the past?
Yes_____
No _____
• If yes, how many episodes o f treatment have you been through?

•

Are you currently taking prescription medication(s) for depression?
Yes
No _____
* If yes, what medication(s) are you taking and what is the dosage?

•

Have you taken prescription medication(s) for depression in the past?
Yes_____
No _____
• If yes, what medication(s)? ______________________________

•

Are you currently in treatment for any psychological conditions) other than
depression?
Yes (please specify)________________________________________
No _____

•

Have you been treated for any psychological conditions) other than depression
the past?
Yes (please specify)________________________________________
No _____

Current Stressors:

_____________________

__________________
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The Beck Depression Inventory-Second Edition is copyrighted by Aaron T. Beck,
1996. Persons interested in obtaining information regarding this instrument should
contact The Psychological Corporation, 555 Academic Court, San Antonio, Texas
78204-2498.
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The Revised Hamilton Rating Scale for Depression is copyrighted by W. L. Warren,
1994. Persons interested in obtaining information regarding this instrument should
contact Western Psychological Services, 12031 Wilshire Boulevard, Los Angeles,
California 90025-1251.
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M a s te r

Name
Code

L i s t

o f

S u b je c ts

Last 4

Research
Number

1.

2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.

*

00

17.

19.
20.
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Assessment Information for Subj.#

Intake Interview:
•

BDI-H Score:_

•

RHRSD Score: _

•

SCID Diagnosis:
• Axis I
•

AxisII

•

Axis El

•

Axis IV

•

GAF Score

Pretreatment (if more than 10 days from intake to first session):
• BDI-n Score_____
•

RHRSD Score _____

BDI-II scores during treatment:
•
•
•
•
•
•
•
•
•
•

Week
Week
Week
Week
Week
Week
Week
Week
Week
Week

I ______

2 _____
3 _____
4 _____
5 _____
6
7
8 _____
9 _____
10
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Post-treatment:
•

BDI-E score_____

•

RHRSD sco re_____

3 Month Follow-up:
•

BDI-n score_____

•

RHRSD score_____

•

SCID Diagnosis:
• Axis I

_________________

•

Axis II

_________________

•

Axis IH

_________________

•

Axis IV

_________________

•

GAF Score

_________________

All Data Collection Complete:

Initials:_______Date
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BAGT Termination Interview Questionnaire
Subject Number:___________________

Date:

Medication Use Changes During BAGT Treatment:
Did you start a new antidepressant medication?
If yes, which medication(s)?

Yes

No

Did you stop and antidepressant medication?
If yes. which medicationfsY?

Yes

No

Did the dosage of your antidepressant medication change? Yes
If ves. did it increase or decrease?

No

Psychotherapy Use During BAGT Treatment:
Did you receive individual therapy during BAGT?
If yes. how often did you see your therapist?
Did you attend another therapy group during BAGT?
If yes. how often and what type of group?

Yes

No

Yes

No

Rating Behavioral Activation Group Therapy
1 = much worse 3 = same 5 = much better
How did BAGT compare to individual therapy?
1 2 3 4 5 N/A
How did BAGT compare to other group therapies?
1 2 3 4 5 N/A
How did the BA approach compare to other approaches?
1 2 3 4 5 N/A
How effective was BAGT compared to other approaches?
1 2 3 4 5 N/A
How did BAGT compare to medication treatment?
I 2 3 4 5 N/A
How effective was BAGT compared to medication treatment? 1 2 3 4 5 N/A
How would you rate this therapy overall?
1 2 3 4 5 N/A
How would you rate your depression as a result
1 2 3 4 5 N/A
o f receiving BAGT?
1 = strong no 3 = maybe 5 =: strong yes
Would you recommend BAGT to a friend?
1 2 3 4 5 N/A
Would you go through BAGT again?
I 2 3 4 5 N/A
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BAGT Follow-up Questionnaire
S u b ject#:________________________

D ate:______

Are you currently in individual therapy?
Yes
No
If yes, how often?________________________________________

Are you currently in group therapy?
Yes
No
If yes, how often?
_____________________________

Are you currently taking medication for depression?

Yes

No

How is your depression compared to 6 months ago?_____________

Did the group provide long-term benefits for managing depression?
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Kalamazoo. Michigan 49008*3899

Human Subjects institutional Review Board

WESTERN MICHIGAN UNIVERSITY

Date:

11 January 1999

To:

Richard Spates, Principal Investigator
Jeffrey Porter, Student Investigator for dissertation

From: Sylvia Culp, Chair
Re:

HSIRB Project Number 98-10-17

This letter will serve as confirmation that your research project entitled
“Southwestern Michigan Treatment of Depression Collaborative Study:
Behavioral Activation Group Therapy: An Initial Investigation" has been
approved under the full category of review by the Human Subjects Institutional
Review Board. The conditions and duration of this approval are specified in the
Policies of Western Michigan University. You may now begin to implement the
research as described in the application.
Please note that you may only conduct this research exactly in the form it was
approved. You must seek specific board approval for any changes in this project.
You must also seek rcapproval if the project extends beyond the termination dale
noted below. In addition if there arc any unanticipated adverse reactions or
unanticipated events associated with the conduct of this research, you should
immediately suspend the project and contact the Chair of the HSIRB for
consultation.
The Board wishes you success in the pursuit of your research goals.
Approval Termination:

11 January 2000
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